{
  "generated_at": "2026-01-25T16:42:45.740345",
  "public_days": 7,
  "summary": {
    "total_catalysts": 693,
    "this_week": 19,
    "next_week": 4,
    "this_month": 26,
    "big_movers": 23,
    "by_type": {
      "PDUFA": 38,
      "AdCom": 0,
      "Phase 3": 109,
      "Phase 2": 134,
      "Phase 1": 181,
      "Initiation": 146,
      "Submission": 84,
      "Other": 1
    }
  },
  "catalysts": [
    {
      "ticker": "XNCR",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 1010.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AGIO",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "Tebapivat (AG-946)",
        "indication": "Myelodysplastic syndrome",
        "category": "Hematology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Agios Pharmaceuticals Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 51,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALZN",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "AL001",
        "indication": "Bipolar disease",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Alzamend Neuro ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "AQST",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Anaphylm\u2122 (dibutepinephrine) sublingual film",
        "indication": "Anaphylaxis",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Aquestive Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AVBP",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Firmonertinib",
        "indication": "1L Non-small Cell Lung Cancer (NSCLC) w/ EGFR exon 20 insertion mutations",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ArriVent",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AXSM",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "AXS-12 (reboxetine) (NE reuptake inhibitor) ",
        "indication": "Narcolepsy",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Axsome Therapeutics Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "BEAM",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "BEAM-302",
        "indication": "Alpha-1 Antitrypsin Deficiency",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Beam Therapeutics Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CALC",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Auxora\u2122",
        "indication": " Acute Kidney Injury (AKI)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "CalciMedica",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRVS",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Soquelitinib",
        "indication": "Autoimmune Lymphoproliferative Syndrome ",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Corvus ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IBRX",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Anktiva (N-803) + PD-L1 CAR-NK (IL-15 Agonist)",
        "indication": "Recurrent Glioblastoma",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ImmunityBio ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IOVA",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Iovance TIL (LN-145)",
        "indication": "Cancer, Endometrial cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Iovance Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "JUNS",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2a",
        "description": "Phase 2a Initiation",
        "drug_name": "JOTROL (Resveratrol)",
        "indication": "Parkinson's disease",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Jupiter Neurosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KYMR",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "KT-579",
        "indication": "Inflammatory disorders",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Kymera Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MTSR",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "MET-233i + MET-097i",
        "indication": "Overweight or obesity",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Metsera",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "OSTX",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "OST-HER2",
        "indication": "Pediatric lung metastatic osteosarcoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "OS Therapies",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 86.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "PHAR",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Leniolisib",
        "indication": "Activated Phosphoniositide 3-kinase Delta Syndrome (APDS in children 4\u201311) (label expansion)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Pharming Group",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PYPD",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "D-PLEX-100",
        "indication": "Surgical site infection",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Polypid",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 13,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "RCUS",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Casdatifan (AB521) (HIF-2a Inhibitor)",
        "indication": "Cancer, Late-line clear cell renal cell carcinoma (ccRCC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arcus Biosciences ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RLMD",
      "date": "2026-01-31",
      "date_display": "Jan 31, 2026",
      "weekday": "Saturday",
      "days_until": 6,
      "is_public": true,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Sepranolone",
        "indication": "Tourette syndrome",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Relmada Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ARTV",
      "date": "2026-02-05",
      "date_display": "Feb 05, 2026",
      "weekday": "Thursday",
      "days_until": 11,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "AlloNK\u00ae (AB-101) + rituximab",
        "indication": "B-cell non-Hodgkin\u2019s lymphoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Artiva Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "XCUR",
      "date": "2026-02-05",
      "date_display": "Feb 05, 2026",
      "weekday": "Thursday",
      "days_until": 11,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Update",
        "drug_name": "Burixafor",
        "indication": "Multiple myeloma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Exicure",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KOD",
      "date": "2026-02-07",
      "date_display": "Feb 07, 2026",
      "weekday": "Saturday",
      "days_until": 13,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "KSI-101",
        "indication": "Macular edema (retinal fluid) secondary to inflammation (MESI)",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Kodiak Sciences Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RGNX",
      "date": "2026-02-08",
      "date_display": "Feb 08, 2026",
      "weekday": "Sunday",
      "days_until": 14,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Clemidsogene lanparvovec (RGX-121)",
        "indication": "Mucopolysaccharidosis II (MPS II), aka Hunter syndrome",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Regenxbio",
        "mcap_millions": 715.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [
        {
          "code": "PR",
          "label": "Priority Review",
          "color": "orange"
        },
        {
          "code": "AA",
          "label": "Accelerated Approval",
          "color": "yellow"
        },
        {
          "code": "RMAT",
          "label": "RMAT",
          "color": "teal"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": true,
        "mover_score": 82,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 65,
        "cont_rating": null,
        "play_type": "Standard",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 89.3
      },
      "meta": {
        "has_position": true,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PRAX",
      "date": "2026-02-15",
      "date_display": "Feb 15, 2026",
      "weekday": "Sunday",
      "days_until": 21,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Ulixacaltamide (PRAX-944) (T-type calcium channel blocker) ",
        "indication": "Essential tremor",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Praxis Precision Medicines",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "MDNAF",
      "date": "2026-02-17",
      "date_display": "Feb 17, 2026",
      "weekday": "Tuesday",
      "days_until": 23,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "MDNA55 (Bizaxofusp)",
        "indication": "Glioblastoma, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Medicenna Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VNDA",
      "date": "2026-02-21",
      "date_display": "Feb 21, 2026",
      "weekday": "Saturday",
      "days_until": 27,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Bysanti\u2122 (milsaperidone)",
        "indication": "Schizophrenia, Mental health, Bipolar disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Vanda Pharmaceuticals Inc.",
        "mcap_millions": 456.0,
        "short_interest_pct": 7.88
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 72.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 72,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": true,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ETON",
      "date": "2026-02-25",
      "date_display": "Feb 25, 2026",
      "weekday": "Wednesday",
      "days_until": 31,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "ET-600 (Desmopressin Oral Solution)",
        "indication": "Diabetes insipidus",
        "category": "Metabolic/Liver",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Eton Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GOSS",
      "date": "2026-02-28",
      "date_display": "Feb 28, 2026",
      "weekday": "Saturday",
      "days_until": 34,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data",
        "drug_name": "Seralutinib (GB002)",
        "indication": "Pulmonary Arterial Hypertension (PAH)",
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 590.0,
        "short_interest_pct": 3.6
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 60,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": true,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ASND",
      "date": "2026-02-28",
      "date_display": "Feb 28, 2026",
      "weekday": "Saturday",
      "days_until": 34,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "TransCon CNP",
        "indication": "Achondroplasia",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ascendis Pharma ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 69,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BFRI",
      "date": "2026-02-28",
      "date_display": "Feb 28, 2026",
      "weekday": "Saturday",
      "days_until": 34,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Ameluz\u00ae ",
        "indication": "Actinic keratosis",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Biofrontera",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BFRI",
      "date": "2026-02-28",
      "date_display": "Feb 28, 2026",
      "weekday": "Saturday",
      "days_until": 34,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Ameluz\u00ae ",
        "indication": "Moderate to Severe Acne Vulgaris",
        "category": "Dermatology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Biofrontera",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BMRN",
      "date": "2026-02-28",
      "date_display": "Feb 28, 2026",
      "weekday": "Saturday",
      "days_until": 34,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "PALYNZIQ\u00ae (pegvaliase-pqpz)",
        "indication": "Phenylketonuria",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Biomarin Pharmaceutical Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "COGT",
      "date": "2026-02-28",
      "date_display": "Feb 28, 2026",
      "weekday": "Saturday",
      "days_until": 34,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "NDA",
        "description": "NDA Acceptance for review",
        "drug_name": "Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) ",
        "indication": "Nonadvanced systemic mastocytosis (NonAdvSM)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Cogent Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 21,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GLUE",
      "date": "2026-02-28",
      "date_display": "Feb 28, 2026",
      "weekday": "Saturday",
      "days_until": 34,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "MRT-2359",
        "indication": "Solid tumor/s, Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Monte Rosa Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 38.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VIR",
      "date": "2026-02-28",
      "date_display": "Feb 28, 2026",
      "weekday": "Saturday",
      "days_until": 34,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "VIR-5500 + ARPIs",
        "indication": "Metastatic castration resistant prostate cancer (mCRPC) ",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Vir Biotechnology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LNTH",
      "date": "2026-03-06",
      "date_display": "Mar 06, 2026",
      "weekday": "Friday",
      "days_until": 40,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "PYLARIFY (Piflufolastat F 18)",
        "indication": "PSMA PET Imaging Agent in Prostate cancer ",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lantheus Holdings",
        "mcap_millions": 4340.0,
        "short_interest_pct": 8.89
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BMY",
      "date": "2026-03-06",
      "date_display": "Mar 06, 2026",
      "weekday": "Friday",
      "days_until": 40,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Sotyktu (deucravacitinib)",
        "indication": "Psoriatic arthritis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bristol-Myers Squibb",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 72,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RYTM",
      "date": "2026-03-20",
      "date_display": "Mar 20, 2026",
      "weekday": "Friday",
      "days_until": 54,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "IMCIVREE\u2122 (Setmelanotide)",
        "indication": "Acquired Hypothalamic Obesity (HO)",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Rhythm Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LNTH",
      "date": "2026-03-29",
      "date_display": "Mar 29, 2026",
      "weekday": "Sunday",
      "days_until": 63,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "LNTH-2501 (Ga 68 edotreotide)",
        "indication": "Neuroendocrine tumors (NETs)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lantheus Holdings",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMMP",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Eftilagimod alfa (efti) + Keytruda",
        "indication": "Non-small cell lung carcinoma (1L NSCLC) ",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immutep",
        "mcap_millions": 447.46,
        "short_interest_pct": 3.59
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 55,
        "cont_rating": null,
        "play_type": "Standard",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": true,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARQT",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "ZORYVE\u00ae (ARQ-151) topical roflumilast cream 0.05%",
        "indication": "Atopic dermatitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arcutis Biotherapeutics",
        "mcap_millions": 3498.0,
        "short_interest_pct": 22.16
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TBPH",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Ampreloxetine (TD-9855)",
        "indication": "Multiple System Atrophy, Neurogenic orthostatic hypotension",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Theravance Biopharma",
        "mcap_millions": 965.0,
        "short_interest_pct": 9.7
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AVBP",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 900.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KPTI",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 145.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KOD",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Tarcocimab (KSI-301) (anti-VEGF)",
        "indication": "Non-proliferative diabetic retinopathy",
        "category": "Ophthalmology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Kodiak Sciences Inc.",
        "mcap_millions": 1650.0,
        "short_interest_pct": 21.9
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KPTI",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "XPOVIO (Selinexor) (XPO1 inhibitor) + ruxolitinib",
        "indication": "Myelofibrosis",
        "category": "Hematology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Karyopharm Therapeutics",
        "mcap_millions": 115.54,
        "short_interest_pct": 19.0
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "VYVGART/Efgartigimod (ARGX-113) (FcRn Blocker)",
        "indication": "Ocular Myasthenia Gravis",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": 49500.0,
        "short_interest_pct": 3.68
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 96.4
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ADAG",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Muzastotug (ADG126) + KEYTRUDA\u00ae (pembrolizumab)",
        "indication": "Colorectal cancer (Advanced MSS CRC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Adagene Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALKS",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "ALKS 2680 (RDC-264177)",
        "indication": "Narcolepsy Type 1",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Alkermes plc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ALZN",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "AL001",
        "indication": "Healthy Subjects (Baseline Study)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Alzamend Neuro ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANRO",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": " ALTO-101",
        "indication": "Cognitive Impairment Associated with Schizophrenia ",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Alto Neuroscience",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 41,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANTX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Epetraborole (LeuRS Inhibitor)",
        "indication": "M. Abscessus Lung Disease",
        "category": "Respiratory",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "AN2 Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "APGE",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "APG777",
        "indication": "Atopic dermatitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Apogee Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARQT",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "ARQ-234",
        "indication": "Moderate to severe atopic dermatitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Arcutis Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 55.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ATAI",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "EMP-01 (3,4-methylenedioxy-methamphetamine [MDMA] derivative)",
        "indication": "Social Anxiety Disorder",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ATAI Life Sciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AZTR",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "ATR12-351 (ATR-12)",
        "indication": "Netherton syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Azitra",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BCAX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "Ficerafusp alfa",
        "indication": "1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bicara Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 32,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BCRX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "BCX17725",
        "indication": "Netherton syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "BioCryst Pharmaceuticals Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BLRX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "GLIX1 (DNA Damage Response)",
        "indication": "Glioblastoma, Solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "BioLineRx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CADL",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "CAN-2409 + Valacyclovir w/ ICI treatments",
        "indication": "Lung cancer, Cancer, Solid tumor/s, III/IV Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Candel Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CAPR",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "StealthX vaccine",
        "indication": "SARS-CoV-2",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Capricor Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CBIO",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "CR-001",
        "indication": "Solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Catalyst Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CCCC",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Cemsidomide (CFT7455) +/- dexamethasone",
        "indication": "Hematologic malignancies, Blood disorder, Non-Hodgkin lymphoma, Blood cancer, Multiple myeloma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "C4 Therapuetics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 34.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CGEM",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Zipalertinib",
        "indication": "Non-small cell lung carcinoma (NSCLC) with EGFR Exon 20 Insertion Mutations",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Cullinan Management",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 86.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "CLNN",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "CNM-Au8",
        "indication": "Amyotrophic lateral sclerosis",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Clene Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "CLNN",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Update",
        "drug_name": "CNM-Au8",
        "indication": "Amyotrophic lateral sclerosis",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Clene Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 23,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CMPS",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "COMP360 (Psilocybin)",
        "indication": "Treatment Resistant Depression",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Compass Pathways",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CNTA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "ORX750 ",
        "indication": "Narcolepsy, Sleep-wake disorder",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Centessa Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CNTA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "ORX142",
        "indication": "Acutely sleep-deprived healthy volunteers",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Centessa Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CNTA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "ORX489 (OX2R Agonist)",
        "indication": "Neurological And Neuropsychiatric Disorders",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Centessa Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CNTB",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "Rademikibart (CBP-201) (Th2 Cell Modulator)",
        "indication": "Bronchoconstriction In Asthma And COPD",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Connect Biopharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 47.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRDF",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Update",
        "drug_name": "Onvansertib + SOC (FOLFIRI + bevacizumab or FOLFOX + bevacizumab)",
        "indication": "Metastatic colorectal cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Cardiff Oncology, Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CTMX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1a",
        "description": "Phase 1a Data readout",
        "drug_name": "CX-2051",
        "indication": "Cancer, Metastatic colorectal cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "CytomX Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "HELP",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "CYB004 (Deuterated Dimethyltryptamine Intramuscular)",
        "indication": "Generalized Anxiety Disorder (GAD)",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Cybin",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DTIL",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Other",
        "stage": "IND",
        "description": "IND Acceptance decision",
        "drug_name": "PBGENE-DMD",
        "indication": "Duchenne Muscular Dystrophy (DMD)",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Precision BioSciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ENTA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "EDP-978 (KIT Inhibitor)",
        "indication": "Chronic Spontaneous Urticaria",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Enanta Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ENTX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Next-Gen EB613 (PTH Agonist)",
        "indication": "Osteoporosis",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Entera Bio Ltd",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ETON",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "ET-700 (Extended-Release Drug)",
        "indication": "Undisclosed Indication",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Eton Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "FGEN",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "FG-3246+ enzalutamide",
        "indication": "Cancer, Castration-resistant prostate cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "FibroGen Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 42,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "FULC",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "Pociredir (FTX-6058)",
        "indication": "Sickle cell disease",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Fulcrum Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 60.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GANX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "GT-02287",
        "indication": "Parkinson's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Gain Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 40.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GLTO",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "GB3226  (formerly BRM-1420)",
        "indication": "Acute myeloid leukemia, Blood cancer, Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Galecto",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 60.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "GUTS",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Revita",
        "indication": "Obesity, Type 2 diabetes",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Fractyl Health",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IDYA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Data readout",
        "drug_name": "Darovasertib (IDE196) + crizotinib",
        "indication": "Solid tumor/s, Metastatic uveal melanoma, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "IDEAYA Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 47,
        "success_prob": 40.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IDYA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "IDE034 (B7H3/PTK7 TOP1 ADC)",
        "indication": "Multiple solid tumors expressing B7H3 and PTK7",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "IDEAYA Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IKT",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2b",
        "description": "Phase 2b Initiation",
        "drug_name": "IkT-001",
        "indication": "Pulmonary Arterial Hypertension (PAH)",
        "category": "Cardiovascular",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Inhibikase Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 4,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IMAB",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "Givastomig (TJ-CD4B/ABL111) combo w/ nivolumab + chemo",
        "indication": " 1L Gastric Cancers",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "I-Mab",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INKT",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "AgenT-797",
        "indication": "Graft-versus-host disease (GvHD), Immune Disorders",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "MiNK Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "INSM",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "Brensocatib",
        "indication": "Hidradenitis suppurativa (HS)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Insmed Incorporated",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IONS",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Zilganersen (ION373)",
        "indication": "Alexander Disease ",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Ionis Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 28,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "IOVA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "IOV-4001",
        "indication": "Cancer, Non-small cell lung carcinoma, Melanoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Iovance Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 38.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IOVA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "IOV-5001 (IL-12 TIL Therapy)",
        "indication": "Cancer, Solid Tumors",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Iovance Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "IRON",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "DISC-0974 (Hepcidin Suppression)",
        "indication": "Inflammatory Bowel Disease With Anemia",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Disc Medicine Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 34.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KROS",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "KER-065",
        "indication": "Duchenne muscular dystrophy",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Keros Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 15,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KYMR",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2b",
        "description": "Phase 2b Initiation",
        "drug_name": "KT-621",
        "indication": "Asthma",
        "category": "Respiratory",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Kymera Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 19,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "LSTA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "Certepetide (LSTA1)",
        "indication": "Pancreatic cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lisata Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LSTA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "LSTA1 + Durvalumab/gemcitabine/nab-paclitaxel",
        "indication": "Pancreatic cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lisata Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LTRN",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "LP-184",
        "indication": "Triple Negative Breast Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Lantern Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 10,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "LTRN",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "LP-184",
        "indication": "Brain tumors (Pediatrics), Atypical Teratoid Rhabdoid Tumors (ATRT) ",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Lantern Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MBRX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Annamycin + Ara-C (Cytarabine)",
        "indication": "Acute myeloid leukemia (AML)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Moleculin Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MCRB",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "SER-155 (Live Biotherapeutic)",
        "indication": "Immune Checkpoint Related Enterocolitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Seres Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MLYS",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Lorundrostat",
        "indication": "Obstructive sleep apnea, Hypertension",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Mineralys Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 24.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MNKD",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "MNKD 201 (nintedanib DPI)",
        "indication": "Lung disease, Idiopathic pulmonary fibrosis",
        "category": "Respiratory",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "MannKind Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 75,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": true,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MNPR",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "ALXN1840 (tiomolybdate choline) ",
        "indication": "Wilson disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Monopar Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "NKTR",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "Rezpegaldesleukin (NKTR-358)",
        "indication": "Atopic dermatitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nektar Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 54,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NMRA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "NMRA-861",
        "indication": "Stable Schizophrenia",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Neumora Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 40.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NRXP",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "NRX-101 ",
        "indication": "Post-traumatic stress disorder (PTSD)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "NRX Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "OCUL",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "AXPAXLI (OTX-TKI) (axitinib intravitreal implant)",
        "indication": "Wet age-related macular degeneration",
        "category": "Ophthalmology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ocular Therapeutix",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 63.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ONCY",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Pelareorep + modified FOLFIRINOX +/- atezolizumab",
        "indication": "Metastatic pancreatic cancer (mPDAC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Oncolytics Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ORIC",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "ORIC-944 + ERLEADA\u00ae (apalutamide) and NUBEQA\u00ae (darolutamide)",
        "indication": "Metastatic castration-resistant prostate cancer (mCRPC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ORIC Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "OSTX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "OST-504",
        "indication": "2L prostate cancer ",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "OS Therapies",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "OVID",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "OV4071",
        "indication": "Parkinson\u2019s disease and Lewy body dementia",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Ovid Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "PALI",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "PALI-2108",
        "indication": "Fibrostenotic Crohn\u2019s Disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Palisade Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PCSA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "NGC- Capecitabine (PCS6422)",
        "indication": "Metastatic breast cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Processa Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PRLD",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "JAK2V617F JH2 (JAK2 Inhibitor)",
        "indication": "Myeloproliferative Neoplasms",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Prelude Therapeutics Incorporated",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "PVLA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "QTORIN Rapamycin ",
        "indication": "Microcystic Lymphatic Malformations",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Palvella Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "QNCX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "EryDex",
        "indication": "Rare genetic disease, Neurological disorder, Ataxia Telangiectasia ",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Quince Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "REGN",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Cemdisiran",
        "indication": "Myasthenia gravis",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Regeneron Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "RYTM",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Interim update",
        "drug_name": "RM-718",
        "indication": "Acquired hypothalamic obesity (HO)",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Rhythm Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 52.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SCYX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "SCY-247",
        "indication": "Fungal infections",
        "category": "Infectious Disease",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "SCYNEXIS",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "SLS",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2a",
        "description": "Phase 2a Initiation",
        "drug_name": "SLS009 (GFH009) +/- venetoclax & azacitidine",
        "indication": "Acute myeloid leukemia",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "SELLAS Life Sciences Group",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "SNDX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Revumenib (SNDX-5613)",
        "indication": "Cancer, Metastatic colorectal cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Syndax Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SNY",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Tolebrutinib",
        "indication": "Multiple sclerosis (MS)",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Sanofi",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 72.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SPRB",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT)",
        "indication": "Sanfilippo Syndrome Type B (MPS IIIB)",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Spruce Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 21,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "SRPT",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "SRP-1003",
        "indication": "Myotonic dystrophy type 1 (DM1)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Sarepta Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TARA",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "TARA-002",
        "indication": "Non-muscle invasive bladder cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Protara Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 41,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TCRX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "TSC-203-A0201, TSC-200-A0201, TSC-204-A0201, TSC-204-C0702,TSC-201-B0702, TSC-204-A0101",
        "indication": "Cancer, Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "TScan Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TECX",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "TX2100",
        "indication": "Hereditary Hemorrhagic Telangiectasia (HHT)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Tectonic Therapeutic",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "UPB",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Verekitug",
        "indication": "Severe asthma",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Upstream Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VERU",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2b",
        "description": "Phase 2b Initiation",
        "drug_name": "Enobosarm",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Veru Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 4,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "VERU",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "Sabizabulin",
        "indication": "Atherosclerotic cardiovascular disease ",
        "category": "Cardiovascular",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Veru Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 42.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "VTVT",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Cadisegliatin (TTP399) ",
        "indication": "Diabetes, Type 2 diabetes",
        "category": "Metabolic/Liver",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "vTv Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "VXRT",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Interim update",
        "drug_name": "VXA-CoV2-1 oral pill",
        "indication": "COVID-19",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Vaxart Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 26,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "WHWK",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "HWK-016 (MUC16 Targeted ADC)",
        "indication": "Ovarian And Endometrial Cancers",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Whitehawk Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "WVE",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "WVE-006",
        "indication": "Alpha-1 Antitrypsin Deficiency",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Wave Life Sciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ZBIO",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Obexelimab (CD19xFcyRIIb)",
        "indication": "Multiple sclerosis",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Zenas BioPharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ZBIO",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Orelabrutinib (BTK Inhibitor)",
        "indication": "Secondary Progressive Multiple Sclerosis",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Zenas BioPharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ZEAL",
      "date": "2026-03-31",
      "date_display": "Mar 31, 2026",
      "weekday": "Tuesday",
      "days_until": 65,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Petrelintide (Amylin Analog Peptide)",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Zealand Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DNLI",
      "date": "2026-04-05",
      "date_display": "Apr 05, 2026",
      "weekday": "Sunday",
      "days_until": 70,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "DNL310 (tividenofusp alfa)",
        "indication": "Hunter syndrome MPS II",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Denali Therapeutics",
        "mcap_millions": 2540.0,
        "short_interest_pct": 4.5
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [
        {
          "code": "PR",
          "label": "Priority Review",
          "color": "orange"
        },
        {
          "code": "AA",
          "label": "Accelerated Approval",
          "color": "yellow"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 62,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BMY",
      "date": "2026-04-08",
      "date_display": "Apr 08, 2026",
      "weekday": "Wednesday",
      "days_until": 73,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Opdivo\u00ae (nivolumab) + AVD Chemotherapy (PD-1 Inhibitor)",
        "indication": "Classical Hodgkin Lymphoma, Stage III/IV, Previously Untreated",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bristol-Myers Squibb",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TVTX",
      "date": "2026-04-13",
      "date_display": "Apr 13, 2026",
      "weekday": "Monday",
      "days_until": 78,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "FILSPARI (Sparsentan)",
        "indication": "Focal segmental glomerulosclerosis (FSGS)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Travere Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 69,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GRCE",
      "date": "2026-04-23",
      "date_display": "Apr 23, 2026",
      "weekday": "Thursday",
      "days_until": 88,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "GTx-104",
        "indication": "Aneurysmal subarachnoid hemorrhage (aSAH)",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Grace Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 69,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MRK",
      "date": "2026-04-28",
      "date_display": "Apr 28, 2026",
      "weekday": "Tuesday",
      "days_until": 93,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Doravirine / Islatravir (DOR/ISL)  ",
        "indication": "Virologically Suppressed HIV-1 Infection",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Merck & Co",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MESO",
      "date": "2026-04-30",
      "date_display": "Apr 30, 2026",
      "weekday": "Thursday",
      "days_until": 95,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Update",
        "drug_name": "Rexlemestrocel",
        "indication": "Chronic lower back pain (CLBP)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Mesoblast",
        "mcap_millions": 2380.0,
        "short_interest_pct": 1.58
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "PR",
          "label": "Priority Review",
          "color": "orange"
        },
        {
          "code": "RMAT",
          "label": "RMAT",
          "color": "teal"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 20,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AXSM",
      "date": "2026-04-30",
      "date_display": "Apr 30, 2026",
      "weekday": "Thursday",
      "days_until": 95,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "AXS-05 ",
        "indication": "Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Axsome Therapeutics Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 80,
        "success_prob": 72.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "COGT",
      "date": "2026-04-30",
      "date_display": "Apr 30, 2026",
      "weekday": "Thursday",
      "days_until": 95,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib",
        "indication": "Cancer, Gastrointestinal stromal tumors",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Cogent Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "PTIX",
      "date": "2026-04-30",
      "date_display": "Apr 30, 2026",
      "weekday": "Thursday",
      "days_until": 95,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "PT00114",
        "indication": "Major depression, anxiety disorders, PTSD, addiction / substance use disorders",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Protagenic Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "INBX",
      "date": "2026-05-15",
      "date_display": "May 15, 2026",
      "weekday": "Friday",
      "days_until": 110,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Ozekibart (INBRX-109) (DR5 agonist)",
        "indication": "Advanced or metastatic, unresectable Chondrosarcoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Inhibrx Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "AZN",
      "date": "2026-05-18",
      "date_display": "May 18, 2026",
      "weekday": "Monday",
      "days_until": 113,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Enhertu",
        "indication": "Early-stage HER2+ breast cancer (neoadjuvant)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Astrazeneca",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MNKD",
      "date": "2026-05-29",
      "date_display": "May 29, 2026",
      "weekday": "Friday",
      "days_until": 124,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Afrezza\u00ae (insulin human) Inhalation Powder",
        "indication": "Type 1 diabetes, Diabetes, Type 2 diabetes",
        "category": "Metabolic/Liver",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MannKind Corporation",
        "mcap_millions": 1650.0,
        "short_interest_pct": 8.6
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 75,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": true,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CING",
      "date": "2026-05-31",
      "date_display": "May 31, 2026",
      "weekday": "Sunday",
      "days_until": 126,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "CTx-1301 (dexmethylphenidate)",
        "indication": "Attention deficit hyperactivity disorder",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Cingulate Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARVN",
      "date": "2026-06-05",
      "date_display": "Jun 05, 2026",
      "weekday": "Friday",
      "days_until": 131,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Vepdegestrant (Mono)",
        "indication": "ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arvinas Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ACHV",
      "date": "2026-06-20",
      "date_display": "Jun 20, 2026",
      "weekday": "Saturday",
      "days_until": 146,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Cytisinicline",
        "indication": "Smoking cessation",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Achieve Life Sciences",
        "mcap_millions": 290.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 55,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 92.9
      },
      "meta": {
        "has_position": true,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARWR",
      "date": "2026-06-25",
      "date_display": "Jun 25, 2026",
      "weekday": "Thursday",
      "days_until": 151,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Plozasiran (ARO-APOC3)  ",
        "indication": "Dyslipidemia",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Arrowhead Pharmaceuticals ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ARQT",
      "date": "2026-06-29",
      "date_display": "Jun 29, 2026",
      "weekday": "Monday",
      "days_until": 155,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "ZORYVE\u00ae (roflumilast) Cream 0.3%",
        "indication": "Plaque psoriasis (Ages 2 to 5)",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arcutis Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PTN",
      "date": "2026-06-29",
      "date_display": "Jun 29, 2026",
      "weekday": "Monday",
      "days_until": 155,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Bremelanotide + PDE5i",
        "indication": "Erectile dysfunction\n",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Palatin Technologies",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRMD",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "REZZAYO (rezafungin)",
        "indication": "Prophylaxis of Fungal Infections",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "CorMedix",
        "mcap_millions": 530.81,
        "short_interest_pct": 21.63
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 62.5
      },
      "meta": {
        "has_position": true,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MIRM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Interim Update",
        "drug_name": "Brelovitug (Monoclonal Antibody)",
        "indication": "Chronic Hepatitis Delta Virus (HDV)",
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 4740.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 89.3
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARWR",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 9000.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ATAI",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 1350.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AVDL",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 2090.0,
        "short_interest_pct": 3.1
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 92.9
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IPHA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 165.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RNA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 10860.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IONS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Pelacarsen ",
        "indication": "Heart disease, Cardiovascular disease ",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ionis Pharmaceuticals",
        "mcap_millions": 13250.0,
        "short_interest_pct": 6.59
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 49.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 92.9
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LLY",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Taltz + Zepbound (Combination Therapy)",
        "indication": "Plaque Psoriasis With Obesity Or Overweight",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Eli Lilly & Company",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 63.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 0.0
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ABVX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Obefazimod",
        "indication": "Moderately to Severely Active Ulcerative Colitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Abivax",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ACET",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Update",
        "drug_name": "ADI-001 (allogeneic CAR gamma-delta T cell therapy)",
        "indication": "Lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Adicet Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ACIU",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "ACI-24.060 (anti-Abeta vaccine)",
        "indication": "Neurological disorder, Alzheimer's disease, Down Syndrome",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "AC Immune SA",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 32.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AKBA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "AKB-9090 (HIF-PH Inhibitor)",
        "indication": "Acute Kidney Injury Associated With Cardiac Surgery",
        "category": "Cardiovascular",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Akebia",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 42.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "AKRO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Efruxifermin (FGF-21 mimetic)",
        "indication": "Pre-cirrhotic MASH with fibrosis stages F2\u2013F3, Non-invasively diagnosed MASLD (F1\u2013F4 fibrosis)",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Akero Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALEC",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Interim update",
        "drug_name": "AL101 (GSK4527226) (Progranulin) ",
        "indication": "Parkinson's disease, Alzheimer's disease, Neurological disorder",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Alector Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 25,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALGS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Pevifoscorvir sodium (ALG-000184)",
        "indication": "Chronic hepatitis B",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Aligos Therapeutics Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 48,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALLO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "ALLO-329 [CD19/CD70 Dual CAR]",
        "indication": "Autoimmune disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Allogene Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALMS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "A-005",
        "indication": "Multiple sclerosis",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Alumis",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ALXO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "ALX2004",
        "indication": "EGFR-expressing solid tumors",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ALX Oncology Holdings Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AMLX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "AMX0114",
        "indication": "Amyotrophic lateral sclerosis",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Amylyx Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 9,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANRO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2b",
        "description": "Phase 2b Initiation",
        "drug_name": "ALTO-207",
        "indication": "Treatment resistant depression (TRD)",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Alto Neuroscience",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 4,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ARCT",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "ARCT-032 ",
        "indication": "Cystic fibrosis",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Arcturus Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Empasiprubart",
        "indication": "Dermatomyositis ",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "ARGX -119",
        "indication": "Amyotrophic lateral sclerosis",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "ARGX-213",
        "indication": "no known indication",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "VYVGART/Efgartigimod (ARGX-113) (FcRn Blocker)",
        "indication": "Graves' Disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ARTV",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "AlloNK\u00ae (AB-101) + rituximab",
        "indication": "Rheumatoid arthritis, Pemphigus vulgaris, Granulomatosis with polyangiitis/microscopic polyangiitis, Systemic lupus erythematosus",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Artiva Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 41,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARVN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1b",
        "description": "Phase 1b Initiation",
        "drug_name": "ARV-102 (LRRK2 Degrader)",
        "indication": "Progressive Supranuclear Palsy",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Arvinas Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "AVDL",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "LUMRYZ (sodium oxybate)",
        "indication": "Idiopathic hypersomnia",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Avadel Pharmaceuticals plc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 62,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AZN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Baxdrostat",
        "indication": "Resistant or uncontrolled hypertension",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Astrazeneca",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 77.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BBIO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Encaleret ",
        "indication": "Autosomal Dominant Hypocalcemia Type 1 ",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "BridgeBio Pharma Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 20,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "BCAB",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Ozuriftamab vedotin (BA3021) (CAB-ROR2-ADC)",
        "indication": "Squamous cell carcinoma of the head and neck (SCCHN)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Bioatla Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "BCAB",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "CAB-EpCAM x CAB-CD3 TCE (BA3182)",
        "indication": "Carcinoma ",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bioatla Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BCYC",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "BT7480 (Nectin-4 CD137, TICA)",
        "indication": "Solid tumor/s, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bicycle Therapeutics plc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BDTX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Silevertinib (BDTX-1535)",
        "indication": "2L/3L NSCLC (Recurrent EGFRm NSCLC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Black Diamond Therapy Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BINV",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "BI-1808 +/- KEYTRUDA",
        "indication": "Cutaneous T-cell lymphoma (CTCL)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "BioInvent International AB",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BIOA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "BGE-102",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "BioAge Labs",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BIVI",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "Bezisterim (NE3107) ",
        "indication": "Early Parkinson's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "BioVie",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BLTE",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Tinlarebant (LBS-008)",
        "indication": "Stargardt disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Belite Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 20,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "BMEA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "BMF-650 (GLP-1 RA)",
        "indication": "Obese, otherwise healthy volunteers",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Biomea Fusion",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BMRN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "VOXZOGO",
        "indication": "Hypochondroplasia",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Biomarin Pharmaceutical Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BMRN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Initiation",
        "drug_name": "BMN 333 (CNP Analogue)",
        "indication": "Achondroplasia",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Biomarin Pharmaceutical Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 4,
        "success_prob": 45.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "BOLD",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "BBI-940",
        "indication": "Indication unknown (ecDNA segregation and inheritance)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Boundless Bio Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "CABA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Rese-cel (formerly CABA-201)",
        "indication": "Systemic lupus erythematosus, Lupus nephritis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Cabaletta Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 35,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CGEM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CLN-978 (CD19xCD3)",
        "indication": "Autoimmune disease, Systemic lupus erythematosus",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Cullinan Management",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CGON",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Cretostimogene",
        "indication": "Non-muscle invasive bladder cancer, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "CG Oncology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CHRS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CHS-114 (SRF114)",
        "indication": "Head and neck squamous cell carcinoma (HNSCC), gastric cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Coherus BioSciences Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CMPX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CTX-8371",
        "indication": "Cancer, Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Compass Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CNTX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CTIM-76",
        "indication": "Testicular cancer, Endometrial cancer, Ovarian cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Context Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CNTX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "CT-202",
        "indication": "Cancer, solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Context Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "COGT",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Bezuclastinib (CGT9486) (KIT exon 17 inhibitor)",
        "indication": "Advanced systemic mastocytosis (AdvSM)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Cogent Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "CRNX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Initiation",
        "drug_name": "Atumelnant  CRN04894 (ACTH antagonist)",
        "indication": "Cushing\u2019s syndrome",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Crinetics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 4,
        "success_prob": 45.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CRSP",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Update",
        "drug_name": "CTX320 Lp(a)",
        "indication": "Atherosclerotic cardiovascular disease ",
        "category": "Cardiovascular",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "CRISPR Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 42.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRSP",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "CTX340 (AGT Gene Editing)",
        "indication": "Refractory Hypertension",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "CRISPR Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 42.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CTNM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "PIPE-791",
        "indication": "Osteoarthritis (OA) and low back pain (LBP)",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Contineum Therapeutics Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DBVT",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Viaskin Peanut (COMFORT Toddlers)",
        "indication": "Peanut Allergic Toddlers",
        "category": "Dermatology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "DBV Technologies",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "DMAC",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Update",
        "drug_name": "DM199 (KLK1 protein)",
        "indication": "Preeclampsia",
        "category": "Other",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "DiaMedica Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DSGN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "DT-818 (GeneTAC Modulator)",
        "indication": "Myotonic Dystrophy Type-1 (DM1)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Design Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "DTIL",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "PBGENE-HBV",
        "indication": "Chronic hepatitis B",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Precision BioSciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DYN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "DYNE-251",
        "indication": "Duchenne muscular dystrophy",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Dyne Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 38,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ELTX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "ELI-002 7P",
        "indication": "Pancreatic cancer, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Elicio Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ENTX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "OPK-88006 (GLP-1/Glucagon Agonist)",
        "indication": "Obesity And Metabolic Disorders",
        "category": "GLP-1/Obesity",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Entera Bio Ltd",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 52.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ERAS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "ERAS-0015",
        "indication": "RAS-mutant (RASm) solid tumors",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Erasca ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ETON",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "INCRELEX/Mecasermin (Mecasermin) (IGF-1 Agonist)",
        "indication": "Severe Primary IGF-1 Deficiency Label Expansion",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Eton Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "EWTX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "EDG-15400",
        "indication": "Heart Failure",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Edgewise Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 42.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "FBRX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "FB102 (Anti-CD122 Antibody)",
        "indication": "Vitiligo",
        "category": "Dermatology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Forte Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GNPX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "REQORSA (quaratusugene ozeplasmid) + Tagrisso",
        "indication": "Lung cancer, Non-small cell lung carcinoma, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Genprex",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GNPX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "REQORSA (quaratusugene ozeplasmid) + Tecentriq",
        "indication": "Small Cell Lung Cancer Extensive Stage",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Genprex",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 38.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GYRE",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "F351 (Hydronidone)",
        "indication": "Chronic hepatitis B, Liver fibrosis",
        "category": "Infectious Disease",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Gyre Therapeutics Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "HCM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "ORPATHYS (Savolitinib) + TAGRISSO",
        "indication": "Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Hutchison China MediTech / Chi-Med",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "HCM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Resubmission",
        "drug_name": "Sovleplenib (HMPL-523) (Syk inhibitor) ",
        "indication": "Primary immune thrombocytopenia",
        "category": "Hematology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Hutchison China MediTech / Chi-Med",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "HCM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Sovleplenib (HMPL-523) (Syk inhibitor)",
        "indication": "Warm autoimmune hemolytic anemia",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Hutchison China MediTech / Chi-Med",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "HOWL",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "WTX-330 (IL-2 INDUKINE\u2122)",
        "indication": "Solid tumor/s, Cancer, Non-Hodgkin lymphoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Werewolf Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IDYA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "IDE397 (MAT2A) + Trodelvy",
        "indication": "MTAP-Deletion Urothelial Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "IDEAYA Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IDYA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Darovasertib (IDE196) + Crizotinib (PKC/ALK Inhibitor)",
        "indication": "Adjuvant Therapy For Primary Uveal Melanoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "IDEAYA Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IMMP",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "IMP761 (LAG-3 agonist) ",
        "indication": "Autoimmune disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immutep",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 55,
        "cont_rating": null,
        "play_type": "Standard",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": true,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMNM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Varegacestat (AL102) (Gamma Secretase Inhibitor)",
        "indication": "Desmoid Tumors",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Immunome",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "IMRX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "Atebimetinib (IMM-1-104)",
        "indication": "1L Pancreatic cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immuneering Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 41,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INBX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Ozekibart (INBRX-109) + FOLFIRI",
        "indication": "Metastatic colorectal cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Inhibrx Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INCY",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Monjuvi (Tafasitamab)",
        "indication": "Diffuse large B-cell lymphoma (DLBCL)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Incyte Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "INCY",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "INCA033989 (MutCALR Monoclonal Antibody)",
        "indication": "Essential Thrombocythemia (MutCALR)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Incyte Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IPHA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Lacutamab (IPH4102)",
        "indication": "Cutaneous T-Cell Lymphoma (CTCL) patients with: S\u00e9zary syndrome (SS) or Mycosis fungoides (MF)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Innate Pharma SA",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 25,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IPHA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Interim update",
        "drug_name": "IPH4502",
        "indication": "Cancer, Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Innate Pharma SA",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IRWD",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Apraglutide (agonist of the GLP-2 receptor)",
        "indication": "Short bowel syndrome (SBS) with intestinal failure (IF) ",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": " Ironwood Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "JAZZ",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Ziihera\u00ae (zanidatamab-hrii) + chemo",
        "indication": "HER2-positive gastroesophageal adenocarcinoma (GEA)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Jazz Pharmaceuticals ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "JBIO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "JADE101",
        "indication": "Immunoglobulin A nephropathy (IgAN)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Jade Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "JBIO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "JADE201",
        "indication": "Rheumatoid arthritis",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Jade Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KRYS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "KB407",
        "indication": "Cystic fibrosis",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Krystal Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 17,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KRYS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "KB408",
        "indication": "Severe alpha-1 antitrypsin deficiency",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Krystal Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KRYS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "KB111 (HSV-1 Gene Therapy)",
        "indication": "Hailey-Hailey Disease",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Krystal Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KTTA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "PAS-004",
        "indication": "Advanced cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Pasithea Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 13,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KURA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "KO-2806",
        "indication": "Solid tumor/s, Non-small cell lung carcinoma, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Kura Oncology ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 47.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KURA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "Ziftomenib + venetoclax/azacitidine (ven/aza) or cytarabine/daunorubicin (7+3)",
        "indication": "Blood cancer, Acute myeloid leukemia, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Kura Oncology ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 60.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KURA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1b",
        "description": "Phase 1b Initiation",
        "drug_name": "KO-2806 +cabozantinib",
        "indication": "Advanced Renal Cell Carcinoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Kura Oncology ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KYTX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Miv-Cel/Mivocabtagene Autoleucel (KYV-101) (CD19 CAR-T)",
        "indication": "Stiff Person Syndrome",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Kyverna Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "LGVN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Lomecel-B (laromestrocel)",
        "indication": "Pediatric Dilated Cardiomyopathy (DCM)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Longeveron Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "LPCN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Brexanolone (LPCN 1154)",
        "indication": "Postpartum depression",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lipocine Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LRMR",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Nomlabofusp (CTI-1601)",
        "indication": "Friedreich\u2019s Ataxia",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Larimar Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 11,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "LTRN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "LP-184 (Synthetic Lethal Agent)",
        "indication": "Bladder Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Lantern Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "LYEL",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Interim update",
        "drug_name": "LYL273 (GCC CAR-T)",
        "indication": "Metastatic Colorectal Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lyell Immunopharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MBX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "MBX 1416",
        "indication": "Post-Bariatric Hypoglycemia",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MBX Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MDNAF",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "MDNA11 (IL-2)",
        "indication": "Cold tumors",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Medicenna Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MIRM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Brelovitug (Monoclonal Antibody)",
        "indication": "Chronic Hepatitis Delta Virus (HDV)",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Mirum Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MLTX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Sonelokimab",
        "indication": "Hidradenitis suppurativa",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MoonLake Immunotherapies",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MNMD",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "MM120 (lysergide D-tartrate)",
        "indication": "Anxiety Disorders",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Mind Medicine (MindMed) Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MRKR",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "MT-601 (Neldaleucel)",
        "indication": "Non-Hodgkin Lymphoma (NHL)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Marker Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MRKR",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "MT-601 (Neldaleucel)  + chemotherapy",
        "indication": "Pancreatic cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Marker Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "NMRA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "NMRA-215 (NLRP3 Inhibitor)",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Neumora Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "NUVL",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Neladalkib (NVL-655)",
        "indication": "TKI pre-treated advanced ALK-positive NSCLC",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Nuvalent",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "NXTC",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "SIM0505 (CDH6 ADC)",
        "indication": "Advanced solid tumors",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "NextCure Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "OCGN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "OCU400",
        "indication": "Retinitis Pigmentosa",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Ocugen",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ONCY",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Pelareorep + gemcitabine, nab-paclitaxel, atezolizumab",
        "indication": "metastatic pancreatic ductal adenocarcinoma (mPDAC)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Oncolytics Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "OPK",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1b",
        "description": "Phase 1b Initiation",
        "drug_name": "MDX2001 (Tetraspecific LASER)",
        "indication": "Cancer, Solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "OPKO Health",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ORKA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "ORKA-002",
        "indication": "Psoriasis",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Oruka Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "OVID",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2a",
        "description": "Phase 2a Initiation",
        "drug_name": "OV329 (GABA-AT inhibitor)",
        "indication": "Epilepsy",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Ovid Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "PASG",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "PBFT02 (AAV1)",
        "indication": "Neurological disorder, Frontotemporal dementia",
        "category": "Gene Therapy",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Passage Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 32.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PBYI",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Interim update",
        "drug_name": "Alisertib",
        "indication": "Cancer, Small cell lung cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Puma Biotechnology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 25,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PHIO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "PH-762",
        "indication": "Cutaneous squamous cell carcinoma (cSCC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Phio Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PHVS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Deucrictibant immediate-release capsules (PHVS416)",
        "indication": "Hereditary angioedema ",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Pharvaris B.V. ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "PMN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "PMN310",
        "indication": "Neurodegenerative disease, Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ProMIS Neurosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 10,
        "success_prob": 40.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PRAX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Elsunersen (PRAX-222)",
        "indication": "Developmental and Epileptic Encephalopathy (SCN2A-DEE)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Praxis Precision Medicines",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PRAX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Data readout",
        "drug_name": "Vormatrigine (PRAX-628)",
        "indication": "Epilepsy, Focal Onset Seizures",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Praxis Precision Medicines",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 47,
        "success_prob": 36.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PRME",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "PM577 (Prime Editing Therapy)",
        "indication": "Wilson's Disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Prime Medicine",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "PRQR",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "AX-0810",
        "indication": "NTCP for Cholestatic diseases",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ProQR",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PTCT",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Votoplam (PTC518)",
        "indication": "Huntington's disease",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "PTC Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "PTN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "PL7737 (MC4R Agonist)",
        "indication": "Obesity, Hypothalamic Obesity, LEPR Deficiency\u2013Related Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Palatin Technologies",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "QURE",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "AMT-191 ",
        "indication": "Fabry disease",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Uniqure NV",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RARE",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "UX701",
        "indication": "Rare diseases, Wilson's disease",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ultragenyx Pharmaceutical Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 46.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RCKT",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Re-initiation",
        "drug_name": "RP-A501",
        "indication": "Immunodeficiency, Danon Disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Rocket Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RGNX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Initiation",
        "drug_name": "Surabgene lomparvovec (sura-vec, ABBV-RGX-314) (Suprachoroidal Delivery)",
        "indication": "Diabetic retinopathy (DR)",
        "category": "Ophthalmology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Regenxbio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 4,
        "success_prob": 45.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 65,
        "cont_rating": null,
        "play_type": "Standard",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": true,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RLMD",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "NDV-01",
        "indication": "Non-muscle invasive bladder cancer (NMIBC)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Relmada Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RLMD",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Sepranolone",
        "indication": "Prader Willi syndrome",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Relmada Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RNAC",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Descartes-08",
        "indication": "Myositis",
        "category": "Dermatology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Cartesian Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RNAZ",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2a",
        "description": "Phase 2a Initiation",
        "drug_name": "TTX-MC138",
        "indication": "Cancer, Solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "TransCode Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 17,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ROIV",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "Brepocitinib ",
        "indication": "Dermatomyositis ",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Roivant",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "RXRX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Update",
        "drug_name": "REC-4881 ",
        "indication": "Familial Adenomatous Polyposis",
        "category": "Other",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Recursion Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RXRX",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "REC-1245",
        "indication": "Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Recursion Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RYTM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Interim Update",
        "drug_name": "IMCIVREE\u2122 (Setmelanotide)",
        "indication": "Congenital Hypothalamic Obesity (HO)",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Rhythm Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 43,
        "success_prob": 60.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SAVA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "Simufilam",
        "indication": "Tuberous Sclerosis Complex (TSC)-related epilepsy",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Cassava Sciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "SDGR",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "SGR-3515",
        "indication": "Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Schrodinger Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SGMO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "ST-920 (isaralgagene civaparvovec)",
        "indication": "Fabry disease",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Sangamo Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 11,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "SLDB",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Update",
        "drug_name": "SGT-003",
        "indication": "Duchenne muscular dystrophy (DMD)",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Solid Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 22,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SRPT",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "SRP-1005",
        "indication": "Huntington\u2019s Disease (HD)",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Sarepta Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "STTK",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Interim update",
        "drug_name": "SL-325",
        "indication": "Inflammatory Bowel Disease (IBD)",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Shattuck Labs Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 31,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TARA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Update",
        "drug_name": "TARA-002 ",
        "indication": "Lymphatic malformations (LMs)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Protara Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TNXP",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "TNX-1500",
        "indication": "Kidney transplantation, Graft-versus-host disease , Hematopoietic cell transplantation ",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Tonix Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "TRVI",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Haduvio (oral nalbuphine ER)",
        "indication": "Idiopathic pulmonary fibrosis chronic cough",
        "category": "Respiratory",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Trevi Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "TSHA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "TSHA-102 ",
        "indication": "Rett syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Taysha Gene Therapies",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TYRA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "TYRA-300",
        "indication": "Low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Tyra Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "UTHR",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Tyvaso (inhaled treprostinil)",
        "indication": "Idiopathic pulmonary fibrosis",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "United Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VNDA",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Tradipitant",
        "indication": "Nausea and Vomiting in Obesity (After GLP-1R Agonist Use)",
        "category": "GLP-1/Obesity",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Vanda Pharmaceuticals Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 60.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 72,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": true,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "VRDN",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Veligrotug (formerly VRDN-001)",
        "indication": "Thyroid Eye Disease ",
        "category": "Ophthalmology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Viridian Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 62,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VSTM",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Avutometinib (VS-6766), + defactinib+gemcitabine/nab-paclitaxel",
        "indication": "First-Line Metastatic Pancreatic Cancer (PDAC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Verastem Oncology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VTRS",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "MR-146 (AAV Gene Therapy)",
        "indication": "Neurotrophic Keratopathy",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Viatris Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 32.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "XNCR",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "XmAb942",
        "indication": "Inflammatory bowel disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Xencor Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ZBIO",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Obexelimab (CD19xFcyRIIb)",
        "indication": "IgG4-related disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Zenas BioPharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ZNTL",
      "date": "2026-06-30",
      "date_display": "Jun 30, 2026",
      "weekday": "Tuesday",
      "days_until": 156,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Azenosertib (ZN-c3) (oral inhibitor of WEE1)",
        "indication": "Uterine disease, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Zentalis Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CORT",
      "date": "2026-07-11",
      "date_display": "Jul 11, 2026",
      "weekday": "Saturday",
      "days_until": 167,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Relacorilant + Nab-paclitaxel",
        "indication": "Platinum-Resistant Ovarian Cancer\u200b ",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Corcept Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CELC",
      "date": "2026-07-17",
      "date_display": "Jul 17, 2026",
      "weekday": "Friday",
      "days_until": 173,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Gedatolisib + palbociclib + fulvestrant (gedatolisib triplet)",
        "indication": "HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer (ABC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Celcuity",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MNKD",
      "date": "2026-07-26",
      "date_display": "Jul 26, 2026",
      "weekday": "Sunday",
      "days_until": 182,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "FUROSCIX ReadyFlow\u2122 Auto-Injector Injection (furosemide)  ",
        "indication": "Edema in Adults with Chronic Heart Failure (CHF) or Chronic Kidney Disease (CKD)",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MannKind Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 77.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 75,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": true,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NRXP",
      "date": "2026-07-29",
      "date_display": "Jul 29, 2026",
      "weekday": "Wednesday",
      "days_until": 185,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "KETAFREE\u2122 (NRX-100) (preservative-free IV ketamine)",
        "indication": "Suicidal Depression",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "NRX Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 72.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VTRS",
      "date": "2026-07-30",
      "date_display": "Jul 30, 2026",
      "weekday": "Thursday",
      "days_until": 186,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Low Dose Estrogen Weekly Patch (Transdermal Contraceptive)",
        "indication": "Contraception",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Viatris Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LNTH",
      "date": "2026-08-13",
      "date_display": "Aug 13, 2026",
      "weekday": "Thursday",
      "days_until": 200,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "MK-6240 (florquinitau) ",
        "indication": "Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lantheus Holdings",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 72.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARWR",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Plozasiran (ARO-APOC3) ",
        "indication": "Severe hypertriglyceridemia",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arrowhead Pharmaceuticals ",
        "mcap_millions": 9180.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 92.9
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KPTI",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "XPOVIO (Selinexor) (XPO1 inhibitor)",
        "indication": "Endometrial cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Karyopharm Therapeutics",
        "mcap_millions": 115.5,
        "short_interest_pct": 16.7
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 89.3
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ABCL",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "ABCL575",
        "indication": "Moderate-to-severe atopic dermatitis (AD)",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "AbCellera",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 55.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANAB",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "BLA",
        "description": "BLA Acceptance for review",
        "drug_name": "Imsidolimab (ANB019) (anti-IL-36R)",
        "indication": "Hidradenitis suppurativa, Generalized pustular psoriasis, EGFRi-mediated skin toxicity, Ichthyosis, Palmoplantar pustulosis, Acne",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "AnaptyBio Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 21,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Empasiprubart ",
        "indication": "Delayed graft function",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ASMB",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "ABI-5366",
        "indication": "Recurrent Genital Herpes Simplex Type 2",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Assembly Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "AURA",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Belzupacap Sarotalocan (Bel-sar) (AU-011)",
        "indication": "Non-Muscle-Invasive Bladder Cancer (NMIBC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Aura Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AVTX",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "AVTX-009",
        "indication": "Hidradenitis suppurativa, Autoimmune disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Avalo Therapeutics ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BIOA",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "BGE-102 (NLRP3 Inhibitor)",
        "indication": "Diabetic Macular Edema",
        "category": "Ophthalmology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "BioAge Labs",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 44.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "BIVI",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Bezisterim (NE3107)",
        "indication": "Neurological symptoms associated with long COVID",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "BioVie",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CATX",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "[212Pb]VMT01 3.0 mCi +/- nivolumab",
        "indication": "MC1R-Positive Metastatic Melanoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Perspective Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CBIO",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "CR-002 (Topoisomerase Inhibitor ADC)",
        "indication": "Solid Tumors",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Catalyst Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "CHRS",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Casdozokitug (casdozo) combination",
        "indication": "Hepatocellular carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Coherus BioSciences Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 48,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CNTB",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Rademikibart /CBP-201 ",
        "indication": "Asthma",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Connect Biopharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CNTX",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CT-95",
        "indication": "Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Context Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "COGT",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib",
        "indication": "First-Line Gastrointestinal Stromal Tumors With Exon 9 Mutations",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Cogent Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CRBP",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Initiation",
        "drug_name": "CRB-701 (SYS6002)",
        "indication": "Solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Corbus Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 9,
        "success_prob": 40.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CRSP",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "CTX460",
        "indication": "Alpha-1 Antitrypsin Deficiency (AATD)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "CRISPR Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "DAWN",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Emi-Le/Emiltatug Ledadotin (Emi-Le) (B7-H4 ADC)",
        "indication": "Cancer, Adenoid Cystic Carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Day One Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DYN",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "DYNE-101",
        "indication": "Myotonic Dystrophy Type 1",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Dyne Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 44,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "EDIT",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "EDIT-401",
        "indication": "Hyperlipidemia, Atherosclerotic cardiovascular disease (ASCVD)",
        "category": "Cardiovascular",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Editas Medicine",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 42.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ELVN",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "ELVN-001",
        "indication": "Chronic Myeloid Leukemia",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Enliven Therapeutics, Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "EQ",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "EQ504 (AhR Modulator)",
        "indication": "Ulcerative Colitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Equillium",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "EXEL",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Zanzalintinib + Immune Checkpoint Inhibitor",
        "indication": "Resected Stage II/III Colorectal Cancer (MRD-Positive)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Exelixis Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "EYPT",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "DURAVYU\u2122 (vorolanib intravitreal insert) (EYP-1901)",
        "indication": "Wet age-related macular degeneration ",
        "category": "Ophthalmology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "EyePoint pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 63.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GLTO",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "DMR-001 (MutCALR Antibody)",
        "indication": "Essential Thrombocythemia, Myelofibrosis",
        "category": "Hematology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Galecto",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 47.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "HRMY",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "BP1.15205",
        "indication": "Narcolepsy, idiopathic hypersomnia and other central disorders of hypersomnolence",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Harmony Biosciences Holdings Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMRX",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Atebimetinib (IMM-1-104) (MEK Inhibitor)",
        "indication": "1L Pancreatic Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Immuneering Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IVVD",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "VYD2311 (Monoclonal Antibody)",
        "indication": "Long COVID / COVID Vaccine Injury",
        "category": "Infectious Disease",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "INVIVYD",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MDWD",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "EscharEx",
        "indication": "Venous Leg Ulcers",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MediWound ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MGNX",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Interim update",
        "drug_name": "Lorigerlimab monotherapy",
        "indication": "Cancer, Platinum-resistant ovarian cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MacroGenics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 25,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MNMD",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "MM120 (lysergide D-tartrate)",
        "indication": "Major depressive disorder",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Mind Medicine (MindMed) Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NGNE",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "NGN-401 ",
        "indication": "Rett syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Neurogene Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NMRA",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "NMRA-898",
        "indication": "Schizophrenia, neuropsychiatric disorders",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Neumora Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 40.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "OCGN",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Interim update",
        "drug_name": "OCU410ST",
        "indication": "Stargardt disease, Rare genetic disease",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ocugen",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 47,
        "success_prob": 45.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "OLMA",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "OP-3136",
        "indication": "Cancer, ER+/HER2- breast cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Olema Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PRLD",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "KAT6A (KAT6A Degrader)",
        "indication": "ER-Positive Breast Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Prelude Therapeutics Incorporated",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "PRME",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "PM647 (Prime Editing Therapy)",
        "indication": "Alpha-1 Antitrypsin Deficiency",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Prime Medicine",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "PTGX",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "PN-477",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Protagonist Therapeutics ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "PYXS",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Micvotabart pelidotin (MICVO, formerly PYX-201)",
        "indication": "Cancer, 2L/3L R/M HNSCC [Arms: EGFRi+PD(L)-1-experienced; platinum/PD(L)-1-experienced]",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Pyxis Oncology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "QTTB",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "Bempikibart (ADX-914) ",
        "indication": "Alopecia areata",
        "category": "Dermatology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Q32 Bio ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RCUS",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Casdatifan + Cabozantinib",
        "indication": "2L+ clear cell renal cell carcinoma (ccRCC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arcus Biosciences ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RPTX",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "RP-1664 ",
        "indication": "Cancer, Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Repare Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SGMO",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "ST-506",
        "indication": "Prion disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Sangamo Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "SION",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "SION-451 ",
        "indication": "Cystic fibrosis ",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Sionna Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 47.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SION",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "SION-719",
        "indication": "Cystic fibrosis ",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Sionna Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SPRY",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "neffy\u00ae (epinephrine nasal spray)",
        "indication": "Acute flares in patients with chronic spontaneous urticaria",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ARS Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SRRK",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Apitegromab (SRK-015) (Myostatin Inhibitor)",
        "indication": "Facioscapulohumeral Muscular Dystrophy",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Scholar Rock Holding Corp",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "STRO",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "STRO-004",
        "indication": "Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Sutro Biopharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TNXP",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "TNX-102 SL",
        "indication": "Major Depressive Disorder",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Tonix Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "XLO",
      "date": "2026-08-15",
      "date_display": "Aug 15, 2026",
      "weekday": "Saturday",
      "days_until": 202,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "XTX501",
        "indication": "Solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Xilio Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "MNOV",
      "date": "2026-08-31",
      "date_display": "Aug 31, 2026",
      "weekday": "Monday",
      "days_until": 218,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "MN-001 (tipelukast)",
        "indication": "Hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM)",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MediciNova",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NUVL",
      "date": "2026-09-18",
      "date_display": "Sep 18, 2026",
      "weekday": "Friday",
      "days_until": 236,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "Zidesamtinib (NVL-520)",
        "indication": "TKI Pre-treated Patients with Advanced ROS1-positive NSCLC",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nuvalent",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KOD",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "KSI-501 (anti-VEGF & IL-6)",
        "indication": "Eye disease , Wet age-related macular degeneration ",
        "category": "Ophthalmology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Kodiak Sciences Inc.",
        "mcap_millions": 1500.0,
        "short_interest_pct": 21.9
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 63.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AARD",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 335.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GERN",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 830.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GNLX",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 114.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMCR",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 1720.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IVA",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 850.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "QNRX",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 16.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RCUS",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 2350.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RZLT",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 180.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AARD",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "ARD-101",
        "indication": "Prader-Willi Syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Aardvark Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 70,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ABCL",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "ABCL635",
        "indication": "Moderate-to-severe vasomotor symptoms (VMS) or \"hot flashes\"",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "AbCellera",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 32.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALMS",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "ESK-001",
        "indication": "Systemic lupus erythematosus ",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Alumis",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALXO",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Evorpacept (ALX148) + Trastuzumab + Chemotherapy (CD47 Blocker)",
        "indication": "Breast Cancer, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ALX Oncology Holdings Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "ARGX-119",
        "indication": "Congenital myasthenic syndrome ",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Data readout",
        "drug_name": "Efgartigimod",
        "indication": "Myositis",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 47,
        "success_prob": 45.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BOLT",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "BDC-4182",
        "indication": "Cancer, Gastric cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bolt Biotherapeutics ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CLDX",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CDX-622",
        "indication": "Inflammatory disease",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Celldex Therapeutics, Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DWTX",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "Halneuron",
        "indication": "Chemotherapy-induced neuropathic pain",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Dogwood Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 47,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LGVN",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "Lomecel-B (laromestrocel)",
        "indication": "Hypoplastic Left Heart Syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Longeveron Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 24.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MLTX",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Sonelokimab",
        "indication": "Palmoplantar pustulosis",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "MoonLake Immunotherapies",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MPLT",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "ML-007C-MA (Undisclosed Mechanism)",
        "indication": "Schizophrenia",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Maplight Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PHVS",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "PHVS719 (deucrictibant extended-release tablets)",
        "indication": "Hereditary angioedema ",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Pharvaris B.V. ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SLN",
      "date": "2026-09-30",
      "date_display": "Sep 30, 2026",
      "weekday": "Wednesday",
      "days_until": 248,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Divesiran",
        "indication": "Polycythemia Vera",
        "category": "Hematology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Silence Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INO",
      "date": "2026-10-30",
      "date_display": "Oct 30, 2026",
      "weekday": "Friday",
      "days_until": 278,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "PDUFA",
        "description": "PDUFA Approval decision",
        "drug_name": "INO-3107",
        "indication": "Recurrent respiratory papillomatosis (RRP)",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Inovio Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 57,
        "success_prob": 86.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "HRMY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 TEMPO study data readout",
        "drug_name": "WAKIX\u00ae (pitolisant) ",
        "indication": "Muscle weakness, Muscle degeneration, Myotonic Dystrophy Type 1",
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 2117.0,
        "short_interest_pct": 3.5
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 50.0
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRVS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 1780.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "FGEN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 30.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RVMD",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 22500.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "XFOR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 393.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ZNTL",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 214.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRVS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Interim Update",
        "drug_name": "Soquelitinib (CPI-818) ",
        "indication": "Peripheral T-cell Lymphomas",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Corvus ",
        "mcap_millions": 1910.0,
        "short_interest_pct": 10.34
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "AA",
          "label": "Accelerated Approval",
          "color": "yellow"
        },
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 51,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 82.1
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BMY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "KarXT (M1/M4 muscarinic agonist)",
        "indication": "Schizophrenia, Mental health, Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bristol-Myers Squibb",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 0.0
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MRNA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "mRNA-4157/V940 +KEYTRUDA ",
        "indication": "Cancer, Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Moderna",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 0.0
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RARE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "GTX-102",
        "indication": "Angelman Syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ultragenyx Pharmaceutical Inc.",
        "mcap_millions": 2277.0,
        "short_interest_pct": 9.24
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SMMT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Ivonescimab (SMT112) ",
        "indication": "1L Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Summit Therapeutics",
        "mcap_millions": 14000.0,
        "short_interest_pct": 30.19
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "BIC",
          "label": "Best-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": 100.0
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ABVX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "Obefazimod",
        "indication": "Crohn\u2019s Disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Abivax",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ACET",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "ADI-001",
        "indication": "Rheumatoid Arthritis (RA)",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Adicet Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ACRS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Bosakitug (ATI-045)",
        "indication": "Atopic dermatitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Aclaris Therapeutics Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ACRS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "ATI-052",
        "indication": "Asthma, Atopic dermatitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Aclaris Therapeutics Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 55.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ACTU",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "Oral Elraglusib (GSK-3\u03b2 Inhibitor) ",
        "indication": "Advanced Cancers Including Refractory Metastatic Melanoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Actuate Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ADAG",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Neoadjuvant Muzastotug (ADG126)",
        "indication": "Colorectal cancer , Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Adagene Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ADCT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "ZYNLONTA (Loncastuximab Tesirine) + COLUMVI (glofitamab)",
        "indication": "Diffuse large B-cell lymphoma (DLBCL)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ADC Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AKBA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "AKB-097 (Complement Inhibitor)",
        "indication": "IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Akebia",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "AKTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "AKTX-101 (Spliceosome Modulator)",
        "indication": "K-Ras G12V Mutated Pancreatic Ductal Adenocarcinoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Akari Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ALEC",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "AL137 (Amyloid Beta Antibody)",
        "indication": "Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Alector Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ALLO",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Cemacabtagene Ansegedleucel (cema-cel)",
        "indication": "Cancer, Diffuse large B cell lymphoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Allogene Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALMS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "ESK-001",
        "indication": "Moderate-to-severe plaque psoriasis",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Alumis",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ALT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Pemvidutide (ALT-801) (GLP-1R/GCGR)",
        "indication": "Alcohol Use Disorder (AUD)",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Altimmune Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 41,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANAB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "ANB033 (anti-CD122 antagonist antibody)",
        "indication": "Inflammatory disease",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "AnaptyBio Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANAB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Jemperli/Dostarlimab (PD-1 Antagonist)",
        "indication": "Locally Advanced dMMR/MSI-H Rectal Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "AnaptyBio Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANNX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Tanruprubart (ANX005) (IV) ",
        "indication": "Guillian-Barre syndrome",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Annexon Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ANNX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Vonaprument (ANX007) (IVT)",
        "indication": "Dry age-related macular degeneration (AMD) with geographic atrophy (GA)",
        "category": "Ophthalmology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Annexon Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 63.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANNX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1a",
        "description": "Phase 1a Data readout",
        "drug_name": "ANX1502",
        "indication": "Cold agglutinin disease",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Annexon Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANRO",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "ALTO-100",
        "indication": "Bipolar depression",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Alto Neuroscience",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ANTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "AN2-502998",
        "indication": "Chagas disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "AN2 Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "APGE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "APG279 (APG777 + APG990)",
        "indication": "Atopic Dermatitis (AD)",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Apogee Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 55.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARDX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "RDX10531 (NHE3 Inhibitor)",
        "indication": "Multiple Therapeutic Areas",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Ardelyx Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "TSP-101 (Fn14 Inhibitor)",
        "indication": "Autoimmune Disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "ARGX-121 (IgA Modulator)",
        "indication": "IgA Nephropathy",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ARGX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Update",
        "drug_name": "ARGX-124 (FcRn Modulator)",
        "indication": "No Known Indication",
        "category": "Other",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARQT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Update",
        "drug_name": "ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor)",
        "indication": "Vitiligo",
        "category": "Dermatology",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Arcutis Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARVN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "ARV-102",
        "indication": "Neurodegenerative disease, Parkinson's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arvinas Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 40.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARVN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "ARV-6723 (HPK1 Degrader)",
        "indication": "Advanced Solid Tumors",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Arvinas Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ARWR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "ARO-INHBE",
        "indication": "Obesity, Metabolic disorder",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arrowhead Pharmaceuticals ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 42.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ATAI",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "VLS-01 (buccal film DMT)",
        "indication": "Treatment Resistant Depression",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ATAI Life Sciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ATOS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "(Z)-Endoxifen (Estrogen Modulator)",
        "indication": "Metastatic Breast Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Atossa Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ATYR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "ATYR0101",
        "indication": "Pulmonary fibrosis",
        "category": "Respiratory",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "aTyr Pharma, Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 47.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "AURA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Belzupacap Sarotalocan (AU-011) (Virus-Like Conjugate)",
        "indication": "Metastases To The Choroid",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Aura Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AURA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Belzupacap Sarotalocan (AU-011) (Virus-Like Conjugate)",
        "indication": "Cancers Of The Ocular Surface",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Aura Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BBIO",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Encaleret",
        "indication": "Post-Surgical Hypoparathyroidism",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "BridgeBio Pharma Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "BCAX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "Ficerafusp alfa -/+ Pembrolizumab",
        "indication": "3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bicara Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 17,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BCYC",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Zelenectide pevedotin (zele, formerly BT8009)",
        "indication": "Solid tumor/s, Cancer, NECTIN4-amplified breast cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bicycle Therapeutics plc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BHVN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "BHV-1300",
        "indication": "Rheumatoid arthritis, Autoimmune disease, Graves\u2019 disease ",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Biohaven Pharmaceutical Holding Company",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "BHVN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Taldefgrobep alfa (BHV-2000) ",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Biohaven Pharmaceutical Holding Company",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BINV",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "BI-1206 + KEYTRUDA",
        "indication": "Treatment-na\u00efve NSCLC patients, uveal melanoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "BioInvent International AB",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BMEA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "BMF-219 (icovamenib) + GLP-1-based therapy",
        "indication": "Severe insulin-deficient type 2 diabetes patients",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Biomea Fusion",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BMEA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Icovamenib + GLP-1 based therapy",
        "indication": " Type 2 diabetes ",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Biomea Fusion",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BRNS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "VTP-1000",
        "indication": "Celiac disease",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Barinthus Biotherapeutics plc [Formerly Vaccitech]",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BTAI",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "sNDA",
        "description": "sNDA Acceptance for review",
        "drug_name": "BXCL501",
        "indication": "Acute agitation associated with schizophrenia & bipolar disorder",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "BioXcel Therapeutics Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 14,
        "success_prob": 72.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CADL",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "CAN-3110",
        "indication": "Solid tumor/s, Cancer, Glioma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Candel Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 14,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CAMP",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "CMP-002 (Antisense Oligonucleotide)",
        "indication": "SYNGAP1-Related Disorders",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "CAMP4 Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CATX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "[212Pb]VMT-\u03b1-NET",
        "indication": "Unresectable or metastatic SSTR2 expressing neuroendocrine tumors (NETs)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Perspective Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CGEM",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Update",
        "drug_name": "CLN-049 (FLT3xCD3)",
        "indication": "Acute myeloid leukemia",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Cullinan Management",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CGEM",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CLN-978 (CD19xCD3)",
        "indication": "Sj\u00f6gren\u2019s disease (SjD)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Cullinan Management",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CLDX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Barzolvolimab (CDX-0159) (KIT receptor) ",
        "indication": "Prurigo nodularis, Skin disease/disorder",
        "category": "Dermatology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Celldex Therapeutics, Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CLLS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "UCART20x22",
        "indication": "Cancer, Non-Hodgkin lymphoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Cellectis",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "COGT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Update",
        "drug_name": "CGT4255 / CNS-penetrant ErbB2 program",
        "indication": "Solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Cogent Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "COGT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CGT4859 (FGFR2 inhibitor)",
        "indication": "Advanced cholangiocarcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Cogent Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CORT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "Miricorilant ",
        "indication": "Non-alcoholic steatohepatitis ",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Corcept Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CORT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Relacorilant + Nab-Paclitaxel & Bevacizumab ",
        "indication": "Platinum-Resistant Ovarian Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Corcept Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRBU",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CB-011",
        "indication": "Multiple myeloma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Caribou Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRMD",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "DefenCath\u00ae (taurolidine and heparin)",
        "indication": "Infectious disease, Catheter related blood stream infections, TPN patients",
        "category": "Infectious Disease",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "CorMedix",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": true,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "CRSP",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "CTX310 (ANGPTL3)",
        "indication": "Atherosclerotic cardiovascular disease ",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "CRISPR Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 42.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRSP",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "CTX112",
        "indication": "Systemic lupus erythematosus",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "CRISPR Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRSP",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "SRSD107",
        "indication": "VTE in patients undergoing total knee arthroplasty (TKA)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "CRISPR Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CRSP",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Update",
        "drug_name": "Zugocaptagene Geleucel/Zugo-Cel (CTX112) (CD19 CAR-T)",
        "indication": "Refractory Immune Thrombocytopenic Purpura And Warm Autoimmune Hemolytic Anemia",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "CRISPR Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 60.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CTMX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1a",
        "description": "Phase 1a Data readout",
        "drug_name": "CX-801 +/- KEYTRUDA",
        "indication": "Cancer, Solid tumor/s, Melanoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "CytomX Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CYCN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "CYC-126 (Anesthetic-Based Therapy)",
        "indication": "Treatment-Resistant Depression",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Cyclerion Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "DAWN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1a",
        "description": "Phase 1a Data readout",
        "drug_name": "DAY301 (formerly MTX-13)",
        "indication": "Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Day One Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DMAC",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Data readout",
        "drug_name": "DM199 (KLK1 protein)",
        "indication": "Heart disease, Ischemic stroke",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "DiaMedica Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 47,
        "success_prob": 38.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DNLI",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "BIIB122/DNL151 (LRRK2 Inhibitor)",
        "indication": "Parkinson's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Denali Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DNLI",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "DNL126 (ETV:SGSH)",
        "indication": "Sanfilippo Syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Denali Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DNTH",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Claseprubart (DNTH103)",
        "indication": "Generalized Myasthenia Gravis (gMG)",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Dianthus Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "DNTH",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Claseprubart (DNTH103)",
        "indication": "Multifocal Motor Neuropathy (MMN)",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Dianthus Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DNTH",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Claseprubart (DNTH103)",
        "indication": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Dianthus Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DNTH",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "LBL-047 (DNTH212) (BDCA2/TACI Inhibitor)",
        "indication": "Systemic Lupus Erythematosus",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Dianthus Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DSGN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "DT-216P2",
        "indication": "Friedreich\u2019s Ataxia",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Design Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DSGN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "DT-168",
        "indication": "Fuchs Endothelial Corneal Dystrophy , Eye disease ",
        "category": "Ophthalmology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Design Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DVAX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Z-1018 (adjuvanted w/ CpG 1018)",
        "indication": "Shingles Vaccine",
        "category": "Infectious Disease",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Dynavax Technologies",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ELDN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Tegoprubart (AT-1501)",
        "indication": "Type 1 diabetes, Islet Cell Transplantation",
        "category": "Metabolic/Liver",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Eledon Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ELEV",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "EO-1022",
        "indication": "Solid tumors ",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Elevation Oncology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ENGN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Detalimogene (EG-70)",
        "indication": "Non-Muscle Invasive Bladder Cancer (NMIBC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "enGene",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ENTA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "EPS-3903 (STAT6 Inhibitor)",
        "indication": "Type 2 Immune-Driven Diseases",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Enanta Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ERAS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "ERAS-4001",
        "indication": "KRAS-mutant (KRASm) solid tumors",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Erasca ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ESPR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "ESP-2001 (ACLY Inhibitor)",
        "indication": "Primary Sclerosing Cholangitis",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Esperion",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "EWTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Sevasemten (EDG-5506)",
        "indication": "Duchenne muscular dystrophy",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Edgewise Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "FATE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "FT819 (CAR-19, TCR-KO) ",
        "indication": "Systemic lupus erythematosus",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Fate Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "FBRX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "FB102 (Anti-CD122 Antibody)",
        "indication": "Alopecia Areata",
        "category": "Dermatology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Forte Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "FDMT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Update",
        "drug_name": "4D-710",
        "indication": "Cystic fibrosis",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "4D Molecular Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "FGEN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "FG-3180 (CD46 PET Tracer)",
        "indication": "Metastatic Castration-Resistant Prostate Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "FibroGen Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GERN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Interim Update",
        "drug_name": "Imetelstat (GRN163L)",
        "indication": "Myelofibrosis",
        "category": "Hematology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Geron Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 58,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GLTO",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "DMR-002 (Mutant Calreticulin Antibody)",
        "indication": "Essential Thrombocythemia, Myelofibrosis",
        "category": "Hematology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Galecto",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 47.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "GMAB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Epkinly/Epcoritamab (GEN3013) (CD3-CD20 Bispecific) + lenalidomide ",
        "indication": "Relapsed Or Refractory Diffuse Large B-Cell Lymphoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Genmab",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GNLX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Olvi-Vec (Olvimulogene nanivacirepvec) ",
        "indication": "Cancer, Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Genelux Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GRTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Tilarginine + nab-paclitaxel + alpelisib ",
        "indication": "Cancer, Metastatic Breast Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Galera Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "GUTS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "RJVA-001",
        "indication": "Inadequately controlled Type 2 diabetes",
        "category": "Metabolic/Liver",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Fractyl Health",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "GYRE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "F351 (Hydronidone)",
        "indication": "Non-alcoholic steatohepatitis , Liver fibrosis",
        "category": "Infectious Disease",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Gyre Therapeutics Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 52.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "HRMY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "WAKIX\u00ae (pitolisant)",
        "indication": "Rare genetic disease, Genetic disorder, Prader-Willi syndrome, Excessive daytime sleepiness",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Harmony Biosciences Holdings Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 77,
        "success_prob": 66.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "HUMA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Humacyte Acellular Tissue Engineered Vessel (ATEV\u2122)",
        "indication": "Dialysis access (AV access)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Humacyte",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "HUMA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "Coronary Tissue Engineered Vessel (Bioengineered Vessel)",
        "indication": "Coronary Artery Bypass Grafting (CABG)",
        "category": "Cardiovascular",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Humacyte",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IFRX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2b",
        "description": "Phase 2b Initiation",
        "drug_name": "INF904",
        "indication": "Skin disease/disorder, Hidradenitis suppurativa",
        "category": "Dermatology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "InflaRx N.V.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 4,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IMAB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Uliledlimab (TJD5) (TJ004309) +/- toripalimab & +/- pembrolizumab",
        "indication": "Cancer, Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "I-Mab",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMCR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "KIMMTRAK (Tebentafusp) +/- anti-PD1",
        "indication": "Cancer, Melanoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immunocore Holdings",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 70,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMCR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "IMC-U120AI",
        "indication": "Atopic dermatitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Immunocore Holdings",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 55.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "IMRX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2a",
        "description": "Phase 2a Initiation",
        "drug_name": "IMM-1-104 + Libtayo",
        "indication": "Cancer, Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Immuneering Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IMTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "ACTengine\u00ae IMA203 GEN1 (PRAME)",
        "indication": "Cutaneous melanoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immatics ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Update",
        "drug_name": "TCER\u00ae IMA402 (PRAME)",
        "indication": "Solid tumor/s, Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Immatics ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1a",
        "description": "Phase 1a Data readout",
        "drug_name": "ACTengine\u00ae IMA203CD8  GEN2 (PRAME) ",
        "indication": "Metastatic melanoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immatics ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMUX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Vidofludimus calcium (IMU-838) ",
        "indication": "Multiple sclerosis, Autoimmune disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immunic",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMVT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "IMVT-1402",
        "indication": "Cutaneous Lupus Erythematosus",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immunovant",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INBX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Data readout",
        "drug_name": "INBRX-106 (OX40 agonist) + Keytruda ",
        "indication": "Head and neck squamous cell carcinoma ",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Inhibrx Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 47,
        "success_prob": 40.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INBX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "INBRX-106",
        "indication": "Non-small cell lung cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Inhibrx Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 38.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INCY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Povorcitinib (JAK1) ",
        "indication": "Vitiligo",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Incyte Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INCY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "INCA33890 (TGF\u03b2R2\u00d7PD-1-directed Bispecific Antibody)",
        "indication": "Solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Incyte Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "INCY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "INCB160058",
        "indication": "Myeloproliferative Neoplasms (MPNs)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Incyte Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 40.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INKT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "AgenT-797 ",
        "indication": "Virus-Induced  Acute Respiratory Disease Syndrome",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MiNK Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INMB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "INKmune\u2122",
        "indication": "Cancer, Prostate cancer, Castration-resistant prostate cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "INmune Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "INMB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "CORDStrom",
        "indication": "Recessive dystrophic epidermolysis bullosa",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "INmune Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "IOBT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "IO112",
        "indication": "Cancer, solid tumor/s",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "IO Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "IONS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "IONIS-MAPTRx (BIIB080)",
        "indication": "Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ionis Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IONS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Ulefnersen (ION363 )",
        "indication": "Amyotrophic lateral sclerosis",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ionis Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IOVA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Iovance TIL (LN-145)",
        "indication": "Non-small cell lung carcinoma (NSCLC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Iovance Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IOVA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "IOV-3001",
        "indication": "Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Iovance Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "IPHA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Monalizumab + durvalumab +  oleclumab",
        "indication": "Non-small cell lung carcinoma, Cancer, Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Innate Pharma SA",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IPHA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "IPH6501 ",
        "indication": "Cancer, Non-Hodgkin lymphoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Innate Pharma SA",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IPSEY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Tazemetostat + rituximab + lenalidomide",
        "indication": "Follicular lymphoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ipsen",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IRON",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "DISC-0974",
        "indication": "Myelofibrosis, Anemia",
        "category": "Hematology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Disc Medicine Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 34.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IRON",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "DISC-3405 (Hepcidin Induction)",
        "indication": "Sickle Cell Disease",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Disc Medicine Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 60.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IVA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Lanifibranor (Pan-PPAR)",
        "indication": "Metabolic dysfunction-associated steatohepatitis (MASH)",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": " Inventiva",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 73,
        "success_prob": 60.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KALV",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "sNDA",
        "description": "sNDA Submission",
        "drug_name": "Sebetralstat (KVD900) (film coated)",
        "indication": "Hereditary angioedema ",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Kalvista Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "KLRS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "TH103",
        "indication": "Neovascular Age-Related Macular Degeneration (nAMD)",
        "category": "Ophthalmology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Kalaris Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 44.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KNSA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "KPL-1161 (IL-1R1 Antagonist)",
        "indication": "Unspecified indication",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Kiniksa Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KPTI",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "XPOVIO (Selinexor) (XPO1 inhibitor) + pomalidomide + dexamethasone",
        "indication": "Multiple myeloma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Karyopharm Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KPTI",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "XPOVIO (Selinexor)",
        "indication": "Myelofibrosis, Primary immune thrombocytopenia",
        "category": "Hematology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Karyopharm Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 48,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KRRO",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "KRRO-121 (RNA Editing Oligonucleotide)",
        "indication": "Hyperammonemia, including urea cycle disorders and hepatic encephalopathy",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Korro Bio, Inc. ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "KRYS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "KB105 ",
        "indication": "Skin disease/disorder, TGM1-deficient lamellar ichthyosis",
        "category": "Dermatology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Krystal Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 44.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KRYS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Interim update",
        "drug_name": "Inhaled KB707",
        "indication": "Solid tumor/s, Lung Metastases, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Krystal Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 17,
        "success_prob": 38.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KTTA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "PAS-004",
        "indication": "Neurofibromatosis type 1 (NF1)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Pasithea Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 40.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "KURA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Ziftomenib + gilteritinib",
        "indication": "Acute myeloid leukemia, Blood cancer, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Kura Oncology ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 60.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LLY",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": " Orforglipron",
        "indication": "Type 2 diabetes",
        "category": "Metabolic/Liver",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Eli Lilly & Company",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 95.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "LSTA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "LSTA1 + gemcitabine/nab-paclitaxel",
        "indication": "Pancreatic cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lisata Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LTRN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "LP-300",
        "indication": "Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lantern Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 48,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LXEO",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "LX2020",
        "indication": "Arrhythmogenic cardiomyopathy",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Lexeo Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MAZE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "MZE782",
        "indication": "Phenylketonuria (PKU), Chronic Kidney Disease (CKD)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Maze Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MBRX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "WP1066",
        "indication": "Cancer, Brain tumor, Solid tumor/s, Glioma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Moleculin Biotech",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MBX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "MBX 4291",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MBX Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MDNAF",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Initiation",
        "drug_name": "MDNA113 (PD-1-IL-2 Bispecific)",
        "indication": "Solid Tumors",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Medicenna Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MDWD",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "EscharEx (Enzymatic Debrider)",
        "indication": "Diabetic Foot Ulcers",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "MediWound ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MGNX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "MGC030 (Topoisomerase 1 ADC)",
        "indication": "Solid Tumor/s, Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "MacroGenics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "MIRM",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "LIVMARLI/Maralixibat (IBAT Inhibitor)",
        "indication": "Pruritus In Rare Cholestatic Conditions",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Mirum Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MNOV",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "MN-166 (ibudilast)",
        "indication": "Neuropathy, Neurological disorder",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MediciNova",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 54,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MNOV",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Data readout",
        "drug_name": "MN-166 (ibudilast)",
        "indication": "Amyotrophic lateral sclerosis",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "MediciNova",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 62,
        "success_prob": 45.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MOLN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "MP0533 (CD33-CD123-CD70)",
        "indication": "High risk myelodysplastic syndromes, Relapsed/refractory acute myeloid leukemia, Acute myeloid leukemia",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Molecular Partners",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MOLN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "MP0726",
        "indication": "Ovarian cancer (mesothelin-overexpressing tumors)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Molecular Partners",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "MREO",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Vantictumab (OMP18R5) (Wnt Pathway Inhibitor)",
        "indication": "Autosomal Dominant Osteopetrosis Type 2",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Mereo BioPharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MRNA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "mRNA-1574",
        "indication": "Human immunodeficiency virus",
        "category": "Gene Therapy",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Moderna",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MRNA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "mRNA-3705",
        "indication": "Rare diseases, Methylmalonic acidemia",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Moderna",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 66.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "MRNA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "mRNA-2808",
        "indication": "Multiple Myeloma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Moderna",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NAMS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Obicetrapib",
        "indication": "ASCVD (Cardiovascular Outcomes)",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "NewAmsterdam Pharma Company NV",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 49.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NBIX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "NBI-1065890",
        "indication": "Neurological disorder",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Neurocrine Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "NBTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "JNJ-1900 (NBTXR3) + Anti-PD-1",
        "indication": "Head and neck cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nanobiotix ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 47.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NBTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "RT + NBTXR3  ",
        "indication": "Cancer, Pancreatic cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nanobiotix ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 17,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NBTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "RT + NBTXR3 + Chemotherapy",
        "indication": "Esophageal cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nanobiotix ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 42,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NCNA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "NUC-7738 (ProTide) +/- pembrolizumab",
        "indication": "Solid tumor/s, Cancer, Melanoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nucana",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NKTR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "NKTR-0165",
        "indication": "Inflammatory disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Nektar Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "NKTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "NKX019 (CAR NK cell therapy)",
        "indication": "Lupus nephritis",
        "category": "Gene Therapy",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nkarta Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NMRA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1b",
        "description": "Phase 1b Initiation",
        "drug_name": "NMRA-511",
        "indication": "Agitation in Alzheimer's Disease, Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Neumora Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "NRIX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Bexobrutideg (NX-5948)",
        "indication": "Cancer, B-cell malignancies",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nurix Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NRIX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1a",
        "description": "Phase 1a Data readout",
        "drug_name": "Zelebrudomide (NX-2127)",
        "indication": "Non-Hodgkin lymphoma, Blood cancer, Cancer, B-cell malignancies, Chronic lymphocytic leukemia, Mantle cell lymphoma, Diffuse large B cell lymphoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nurix Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 60.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NRIX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Bexobrutideg (NX-5948)",
        "indication": "Chronic lymphocytic leukemia (r/r CLL)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Nurix Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "NRIX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "NX-3911 (STAT6 Degrader)",
        "indication": "Autoimmune Diseases",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Nurix Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "NUVL",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "sNDA",
        "description": "sNDA Submission",
        "drug_name": "Zidesamtinib (NVL-520) (ROS1 Inhibitor)",
        "indication": "TKI-Na\u00efve Patients With Advanced ROS1-Positive NSCLC",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Nuvalent",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "NXTC",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Update",
        "drug_name": "LNCB74 (B7-H4 ADC)",
        "indication": "Solid tumor/s, Cancer, Ovarian cancer, Breast cancer, Endometrial cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "NextCure Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "OMER",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1b",
        "description": "Phase 1b Initiation",
        "drug_name": "OMS527 (PDE7 inhibitor)",
        "indication": "Cocaine use disorder",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Omeros Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 70,
        "cont_rating": null,
        "play_type": "Standard",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": true,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ORIC",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "Enozertinib (ORIC-114)",
        "indication": "Solid tumor/s, Advanced malignancies, Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ORIC Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ORIC",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Enozertinib (ORIC-114)",
        "indication": "Cancer, 1L Non-small cell lung carcinoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "ORIC Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ORKA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "ORKA-001",
        "indication": "Psoriasis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Oruka Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ORKA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "ORKA-002 (IL-17A/F Antibody)",
        "indication": "Hidradenitis Suppurativa (HS)",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Oruka Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "PCRX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "PCRX-201 (enekinragene inzadenovec)",
        "indication": "Knee osteoarthritis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Pacira BioSciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PPBT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "IM1240 (Tri-Specific Antibody)",
        "indication": "Advanced Solid Tumors",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Purple Biotech Ltd",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "PRTA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "PRX019",
        "indication": "Neurodegenerative disease",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Prothena Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 40.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PVLA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "QTORIN Rapamycin ",
        "indication": "Angiokeratomas",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Palvella Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 11,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "PYXS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Micvotabart pelidotin (MICVO, formerly PYX-201) + KEYTRUDA\u00ae (pembrolizumab)",
        "indication": "Advanced Solid Tumors (various)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Pyxis Oncology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "QNCX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "EryDex/Dexamethasone Sodium Phosphate (eDSP) (Encapsulated Corticosteroid)",
        "indication": "Duchenne Muscular Dystrophy",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Quince Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RCUS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "Casdatifan + Volrustomig (HIF-2a/PD-1-CTLA-4 Combo)",
        "indication": "Cancer, 1L Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arcus Biosciences ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RCUS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "Casdatifan (AB521) (HIF-2a Inhibitor)",
        "indication": "Cancer, Early-line clear cell renal cell carcinoma (ccRCC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arcus Biosciences ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RCUS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "TNF (TNF Inhibitor)",
        "indication": "Inflammatory and autoimmune diseases, Rheumatoid arthritis, Psoriasis, Inflammatory bowel disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Arcus Biosciences ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 55.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "REPL",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": " RP2 in comb w/ atezolizumab and bevacizumab",
        "indication": "Hepatocellular carcinoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Replimune Group Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RIGL",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Update",
        "drug_name": "Ocadusertib (previously R552)",
        "indication": "Rheumatoid arthritis, Autoimmune disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Rigel Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RIGL",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "R289",
        "indication": "Lower-risk myeloid dysplastic syndrome ",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Rigel Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 22,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RNA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Delpacibart Etedesiran (Del-desiran) (AOC 1001)",
        "indication": "Myotonic Dystrophy Type 1 (DM1)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Avidity Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 70,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RNA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Delpacibart zotadirsen (del-zota) (AOC 1044)",
        "indication": "Duchenne muscular dystrophy (DMD44)",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Avidity Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "RVMD",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Daraxonrasib (RMC-6236)",
        "indication": "Pancreatic ductal adenocarcinoma , Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Revolution Medicines Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RVMD",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "RMC-5127",
        "indication": "no known indication",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Revolution Medicines Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RVPH",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "Brilaroxazine",
        "indication": "Psoriasis, Skin disease/disorder",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Reviva Pharmaceuticals Holdings",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 55.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "RXRX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "REC-102",
        "indication": "Hypophosphatasia (HPP)",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Recursion Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RZLT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Ersodetug",
        "indication": "Tumor Hyperinsulinism (Tumor HI)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Rezolute Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SANA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "SC451 (Islet Cell Therapy)",
        "indication": "Type 1 Diabetes",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Sana Biotechnology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 52.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "SGMT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "TVB-3567",
        "indication": "Acne",
        "category": "Dermatology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Sagimet Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "SLDB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "SGT-212 (dual route)",
        "indication": "Friedreich\u2019s Ataxia",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Solid Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 50.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SMMT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "PDUFA",
        "stage": "BLA",
        "description": "BLA Acceptance for review",
        "drug_name": "Ivonescimab + chemotherapy",
        "indication": "EGFR-mutated, advanced non-squamous NSCLC (2L+ EGFRm NSCLC)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Summit Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SNDX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Axatilimab (SNDX-6352) ",
        "indication": "Idiopathic pulmonary fibrosis",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Syndax Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SRRK",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "SRK-439",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Scholar Rock Holding Corp",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "STRO",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "STRO-006 (Integrin \u03b26 ADC)",
        "indication": "Multiple Solid Tumors",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Sutro Biopharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "SUPN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "SPN-443 (Stimulant Therapy)",
        "indication": "Attention-Deficit/Hyperactivity Disorder",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Supernus Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "SYRE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "SPY003",
        "indication": "Ulcerative colitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Spyre Therapeutics Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TARA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Data readout",
        "drug_name": "IV Choline chloride",
        "indication": "Intestinal failure associated liver disease, Long-term parenteral support",
        "category": "Metabolic/Liver",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Protara Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 47,
        "success_prob": 47.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TARS",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "TP-05",
        "indication": "Lyme disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Tarsus Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "TECX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Data readout",
        "drug_name": "TX45",
        "indication": "Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF) ",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Tectonic Therapeutic",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 47.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TECX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "TX45",
        "indication": "Pulmonary Hypertension (PH) associated with Interstitial Lung Disease (ILD)",
        "category": "Cardiovascular",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Tectonic Therapeutic",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 47.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "TEVA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "TEV-\u2019248 (ICS/SABA)",
        "indication": "Asthma",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Teva Pharmaceutical Industries Ltd",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TLSA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Intranasal Foralumab ",
        "indication": "Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Tiziana Life Sciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TNGX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Vopimetostat (TNG462)",
        "indication": "Pancreatic, lung, MTAP-deleted cancers",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Tango Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 38.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TNXP",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "TNX-2900",
        "indication": "Prader-Willi syndrome",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Tonix Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 11,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "TNXP",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "TNX-102 SL ",
        "indication": "Acute Stress Reaction",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Tonix Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TVTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Pegtibatinase (TVT-058)",
        "indication": "Homocystinuria",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Travere Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "TYRA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "TYRA-300",
        "indication": "Pediatric Achondroplasia",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Tyra Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "TYRA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Dabogratinib (TYRA-300) (FGFR3 Inhibitor)",
        "indication": "Low-Grade Upper Tract Urothelial Carcinoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Tyra Biosciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 26.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "UPB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Verekitug",
        "indication": "Chronic Obstructive Pulmonary Disease (COPD)",
        "category": "Respiratory",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Upstream Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 27.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "URGN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "UGN-103",
        "indication": "Bladder cancer (LG-IR-NMIBC)",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "UroGen Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 81.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "URGN",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "UGN-501 (Oncolytic Virus Therapy)",
        "indication": "High-Grade Non-Muscle Invasive Bladder Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "UroGen Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "UTHR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Ralinepag",
        "indication": "Pulmonary arterial hypertension (PAH)",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "United Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 54.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VIR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "VIR-5818 + Pembrolizumab",
        "indication": "Cancer, HER2-expressing cancers, Metastatic breast cancer, Metastatic colorectal cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Vir Biotechnology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VKTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "VK2735 (Oral formulation)",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Viking Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 52.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VNDA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Bysanti\u2122 (milsaperidone)",
        "indication": "Mental Health, Major depressive disorder",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Vanda Pharmaceuticals Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 72,
        "cont_rating": null,
        "play_type": "LEAP",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": true,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VRTX",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Update",
        "drug_name": "Zimislecel (VX-880)",
        "indication": "Type 1 diabetes",
        "category": "Metabolic/Liver",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Vertex Pharmaceuticals Incorporated",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 25,
        "success_prob": 42.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VXRT",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Update",
        "drug_name": "Second Generation Oral Norovirus Vaccine",
        "indication": "Norovirus",
        "category": "Infectious Disease",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Vaxart Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 16,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VYGR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1a",
        "description": "Phase 1a Data readout",
        "drug_name": "VY7523 (formerly VT- TAU01) [anti-tau antibody]",
        "indication": "Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Voyager Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 40.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "VYGR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "VY1706 (Tau-silencing Gene Therapy)",
        "indication": "No identified indication yet",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Voyager Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "WVE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "NDA",
        "description": "NDA Submission",
        "drug_name": "WVE-N531",
        "indication": "Duchenne muscular dystrophy",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Wave Life Sciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "WVE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "WVE-008",
        "indication": "PNPLA3-I148M liver disease",
        "category": "Metabolic/Liver",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Wave Life Sciences",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 52.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "XENE",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "XEN1101 (Potassium Channel Modulator) ",
        "indication": "Epilepsy, Focal Onset Seizures",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Xenon Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 46.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "XFOR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Mavorixafor (CXCR4 inhibitor)",
        "indication": "Severe Congenital Neutropenia",
        "category": "Rare Disease/Orphan",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "X4 Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 58,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "XNCR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "XmAb819 (ENPP3 x CD3)",
        "indication": "Clear cell renal cell carcinoma (ccRCC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Xencor Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "XNCR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1b",
        "description": "Phase 1b Update",
        "drug_name": "Plamotamab (CD20xCD3) ",
        "indication": "Autoimmune disease, Rheumatoid arthritis",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Xencor Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 21,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "XNCR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Update",
        "drug_name": "XmAb657",
        "indication": "Autoimmune disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Xencor Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 21,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "XNCR",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "XmAb412 (TL1A/IL23p19 Bispecific)",
        "indication": "Inflammatory Bowel Disease",
        "category": "Autoimmune/Inflammation",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Xencor Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "YMAB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "GD2-SADA",
        "indication": "Melanoma, Small cell lung cancer, Sarcoma, Neuroblastoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Y-mAbs Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 47.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ZEAL",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Survodutide (GLP-1/Glucagon Agonist)",
        "indication": "Obesity",
        "category": "GLP-1/Obesity",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Zealand Pharma",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 60.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ZLAB",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Zocilurtatug pelitecan (formerly ZL-1310)",
        "indication": "Neuroendocrine carcinoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Zai Lab",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "ZURA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Tibulizumab",
        "indication": "Hidradenitis Suppurativa",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Zura Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ZVSA",
      "date": "2026-12-31",
      "date_display": "Dec 31, 2026",
      "weekday": "Thursday",
      "days_until": 340,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2a",
        "description": "Phase 2a Data readout",
        "drug_name": "Cholesterol Efflux Mediator\u2122 VAR 200",
        "indication": "Diabetic Kidney Disease",
        "category": "Cardiovascular",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "ZyVersa Therapeutics ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "WHWK",
      "date": "2027-01-31",
      "date_display": "Jan 31, 2027",
      "weekday": "Sunday",
      "days_until": 371,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "HWK-007",
        "indication": "NSCLC, ovarian, endometrial cancers",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Whitehawk Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ARQT",
      "date": "2027-03-31",
      "date_display": "Mar 31, 2027",
      "weekday": "Wednesday",
      "days_until": 430,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Update",
        "drug_name": "ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor)",
        "indication": "Hidradenitis Suppurativa",
        "category": "Other",
        "is_binary": false,
        "is_milestone": false
      },
      "company": {
        "name": "Arcutis Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 18,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ATXS",
      "date": "2027-03-31",
      "date_display": "Mar 31, 2027",
      "weekday": "Wednesday",
      "days_until": 430,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "navenibart (STAR-0215)",
        "indication": "Hereditary angioedema ",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Astria Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "CGEN",
      "date": "2027-03-31",
      "date_display": "Mar 31, 2027",
      "weekday": "Wednesday",
      "days_until": 430,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Interim update",
        "drug_name": "COM701",
        "indication": "Platinum Sensitive Ovarian Cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Compugen",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 31,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BLTE",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 6010.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NBTX",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 1100.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PROK",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 300.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ADVM",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept)",
        "indication": "Wet age-related macular degeneration , Age-related macular degeneration, Eye disease ",
        "category": "Gene Therapy",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Adverum Biotechnologies Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 63.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "FDMT",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "4D-150",
        "indication": "Wet age-related macular degeneration ",
        "category": "Ophthalmology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "4D Molecular Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 63.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "HRMY",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "EPX-100 (clemizole hydrochloride)",
        "indication": "Dravet syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Harmony Biosciences Holdings Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MIRM",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "Volixibat  ",
        "indication": "Primary biliary cholangitis, Liver disease",
        "category": "Metabolic/Liver",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Mirum Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "NBTX",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "NBTXR3 +/- Cetuximab",
        "indication": "Head and neck cancer",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Nanobiotix ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PCVX",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "VAX-31 (PCV Infant)",
        "indication": "Invasive pneumococcal disease",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Vaxcyte",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PRQR",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "AX-2402 (RNA Editing Oligonucleotide)",
        "indication": "Rett Syndrome (MECP2 R270X)",
        "category": "Gene Therapy",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "ProQR",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 50.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "PRTA",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "BMS-986446 (PRX005)",
        "indication": "Alzheimer's disease",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Prothena Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 41,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RAPP",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2a",
        "description": "Phase 2a Initiation",
        "drug_name": "RAP-219",
        "indication": "Bipolar mania",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Rapport Therapeutics Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 2,
        "success_prob": 23.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RAPP",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "RAP-219 (Tarp\u03b38-Specific NAM)",
        "indication": "Primary Generalized Tonic-Clonic Seizures",
        "category": "CNS/Neurology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Rapport Therapeutics Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "RXRX",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1",
        "description": "Phase 1 Data readout",
        "drug_name": "REC-3565",
        "indication": "R/R B-cell Lymphoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Recursion Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 40.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "XLO",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 1",
        "stage": "Phase 1/2",
        "description": "Phase 1/2 Data readout",
        "drug_name": "Efarindodekin Alfa (XTX301)",
        "indication": "Solid tumor/s",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Xilio Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 27,
        "success_prob": 36.0,
        "upside_pct": 35.0,
        "downside_pct": -25.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ZURA",
      "date": "2027-06-30",
      "date_display": "Jun 30, 2027",
      "weekday": "Wednesday",
      "days_until": 521,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "Tibulizumab (ZB-106) (Bispecific Antibody)",
        "indication": "Systemic Sclerosis",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Zura Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BCAX",
      "date": "2027-08-15",
      "date_display": "Aug 15, 2027",
      "weekday": "Sunday",
      "days_until": 567,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Data readout",
        "drug_name": "Ficerafusp alfa + Pembrolizumab",
        "indication": "1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) ",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Bicara Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 62,
        "success_prob": 40.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BIIB",
      "date": "2027-08-15",
      "date_display": "Aug 15, 2027",
      "weekday": "Sunday",
      "days_until": 567,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Zorevunersen",
        "indication": "Dravet Syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Biogen",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "DAWN",
      "date": "2027-08-15",
      "date_display": "Aug 15, 2027",
      "weekday": "Sunday",
      "days_until": 567,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "OJEMDA\u2122 (Tovorafenib) (DAY101) ",
        "indication": "Cancer, Pediatric low-grade glioma ",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Day One Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "HOWL",
      "date": "2027-08-15",
      "date_display": "Aug 15, 2027",
      "weekday": "Sunday",
      "days_until": 567,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "WTX-1011 (STEAP1 T Cell Engager)",
        "indication": "Prostate Cancer",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Werewolf Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "KYMR",
      "date": "2027-08-15",
      "date_display": "Aug 15, 2027",
      "weekday": "Sunday",
      "days_until": 567,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "KT-621 (Oral STAT6 Degrader)",
        "indication": "Atopic dermatitis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Kymera Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "OMER",
      "date": "2027-08-15",
      "date_display": "Aug 15, 2027",
      "weekday": "Sunday",
      "days_until": 567,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 1",
        "description": "Phase 1 Initiation",
        "drug_name": "OncotoX-AML (Oncology Therapeutic)",
        "indication": "Acute Myeloid Leukemia",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Omeros Corporation",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 1,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": 70,
        "cont_rating": null,
        "play_type": "Standard",
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": true,
        "research_available": false,
        "is_phase1": true,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "KRYS",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 8300.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "LXEO",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3",
        "drug_name": null,
        "indication": null,
        "category": null,
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": null,
        "mcap_millions": 550.0,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [
        {
          "code": "ORPHAN",
          "label": "Orphan Drug",
          "color": "purple"
        },
        {
          "code": "BTD",
          "label": "Breakthrough Therapy",
          "color": "green"
        },
        {
          "code": "FIC",
          "label": "First-in-Class",
          "color": "gold"
        },
        {
          "code": "UMN",
          "label": "Unmet Medical Need",
          "color": "red"
        }
      ],
      "movement": {
        "is_big_mover": false,
        "mover_score": null,
        "success_prob": null,
        "upside_pct": null,
        "downside_pct": null
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": true,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ALEC",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "AL050 (GCase Enzyme Replacement)",
        "indication": "Parkinson's disease, Lewy body dementia",
        "category": "Rare Disease/Orphan",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Alector Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 40.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "ARGX",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Efgartigimod  ",
        "indication": "Sj\u00f6gren-Larsson Syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Argenx",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "AURA",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Belzupacap Sarotalocan (Bel-sar)",
        "indication": "Early-Stage Choroidal Melanoma",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Aura Biosciences Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "BMRN",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2",
        "description": "Phase 2 Initiation",
        "drug_name": "Voxzogo/Vosoritide (BMN 111) (CNP Analogue)",
        "indication": "SHOX Deficiency, Turner Syndrome, Noonan Syndrome, Idiopathic Short Stature",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Biomarin Pharmaceutical Inc.",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 3,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "CABA",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "BLA",
        "description": "BLA Submission",
        "drug_name": "Rese-cel (formerly CABA-201)",
        "indication": "Myositis ",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Cabaletta Bio",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "HIGH",
        "color": "red",
        "note": "FDA decision - binary outcome"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 6,
        "success_prob": 90.0,
        "upside_pct": 30.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "COYA",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "COYA 302",
        "indication": "Amyotrophic lateral sclerosis",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Coya Therapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "HRMY",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "WAKIX/Pitolisant HD (H3 Antagonist)",
        "indication": "Narcolepsy",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Harmony Biosciences Holdings Inc",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMVT",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "IMVT-1402",
        "indication": "Graves\u2019 disease ",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immunovant",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMVT",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "IMVT-1402",
        "indication": "Sj\u00f6gren\u2019s Disease (SjD)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immunovant",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IMVT",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "IMVT-1402",
        "indication": "Myasthenia gravis",
        "category": "CNS/Neurology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Immunovant",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "IONS",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "ION582",
        "indication": "Angelman Syndrome",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Ionis Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MDGL",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Rezdiffra (Resmetirom) (MGL-3196)",
        "indication": "Liver disease, Cirrhosis",
        "category": "Metabolic/Liver",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Madrigal Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": true,
        "mover_score": 65,
        "success_prob": 60.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "MIRM",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "MRM-3379",
        "indication": "Fragile X syndrome (FXS)",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Mirum Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "ORKA",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "ORKA-001 (IL-23p19 Antibody)",
        "indication": "Psoriasis",
        "category": "Autoimmune/Inflammation",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Oruka Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 31.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PHAR",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "KL1333",
        "indication": "Mitochondrial disease, primary mitochondrial myopathies",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Pharming Group",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 50,
        "success_prob": 57.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "PHAT",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2",
        "description": "Phase 2 Data readout",
        "drug_name": "VOQUEZNA\u00ae (Vonoprazan)(potassium competitive acid blocker)",
        "indication": "Eosinophilic Esophagitis",
        "category": "Other",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Phathom Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 33,
        "success_prob": 28.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "RCUS",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 3",
        "stage": "Phase 3",
        "description": "Phase 3 Data readout",
        "drug_name": "Quemliclustat + Gemcitabine/Nab-Paclitaxel v.s. Gemcitabine/Nab-Paclitaxel",
        "indication": "1L Pancreatic ductal adenocarcinoma (PDAC)",
        "category": "Oncology",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "Arcus Biosciences ",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 62,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SABS",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Phase 2",
        "stage": "Phase 2b",
        "description": "Phase 2b Data readout",
        "drug_name": "SAB-142",
        "indication": "Stage 3 Type 1 Diabetes (T1D)",
        "category": "Metabolic/Liver",
        "is_binary": true,
        "is_milestone": false
      },
      "company": {
        "name": "SAb Biotherapeutics",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 39,
        "success_prob": 30.0,
        "upside_pct": 45.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": false
      }
    },
    {
      "ticker": "SANA",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Submission",
        "stage": "IND",
        "description": "IND Submission",
        "drug_name": "SG293 (In Vivo CAR-T)",
        "indication": "B-Cell Cancers",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Sana Biotechnology",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "LOW",
        "color": "gray",
        "note": "Non-binary catalyst"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 0,
        "success_prob": 45.0,
        "upside_pct": 35.0,
        "downside_pct": -35.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": false,
        "is_submission": true
      }
    },
    {
      "ticker": "SLGL",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 3",
        "description": "Phase 3 Initiation",
        "drug_name": "Patidegib (SGT-610) (Hedgehog Inhibitor)",
        "indication": "High-Frequency Basal Cell Carcinoma",
        "category": "Oncology",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Sol-Gel",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM-HIGH",
        "color": "orange",
        "note": "Pivotal data - significant move likely"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 5,
        "success_prob": 52.0,
        "upside_pct": 55.0,
        "downside_pct": -55.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    },
    {
      "ticker": "TNXP",
      "date": "2027-12-31",
      "date_display": "Dec 31, 2027",
      "weekday": "Friday",
      "days_until": 705,
      "is_public": false,
      "event": {
        "type": "Initiation",
        "stage": "Phase 2/3",
        "description": "Phase 2/3 Initiation",
        "drug_name": "TNX-4800",
        "indication": "Lyme Disease",
        "category": "Other",
        "is_binary": false,
        "is_milestone": true
      },
      "company": {
        "name": "Tonix Pharmaceuticals",
        "mcap_millions": null,
        "short_interest_pct": null
      },
      "risk": {
        "level": "MEDIUM",
        "color": "yellow",
        "note": "Early efficacy data"
      },
      "designations": [],
      "movement": {
        "is_big_mover": false,
        "mover_score": 4,
        "success_prob": 45.0,
        "upside_pct": 50.0,
        "downside_pct": -45.0
      },
      "risk_factors": {
        "has_crl_history": false,
        "crl_count": 0,
        "true_binary_score": null,
        "true_binary_rating": null
      },
      "analysis": {
        "cont_score": null,
        "cont_rating": null,
        "play_type": null,
        "is_leap_play": false,
        "estimated_pdufa": null,
        "data_completeness": null
      },
      "meta": {
        "has_position": false,
        "research_available": false,
        "is_phase1": false,
        "is_initiation": true,
        "is_submission": false
      }
    }
  ]
}